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ABSTRACT 
The Present study aimed to improve the bioavailability of Rifampicin from fixed dose 
combination with Isoniazid, Pyrazinamide and Ethambutal by Incorporating Rifampicin 
Nanoparticles with fixed dose Combinations. Rifampicin Nanoparticles were Prepared With 
different Concentrations of  PLGA  as Polymer and it was evaluated for  its  physico chemical 
parameters such as FTIR ,DSC, Entrapment Efficiency, Loading Capacity, In vitro drug release 
and  In vivo  pharmacokinetics.  The percentage formation of its metabolite (3FRSV) also 
studied. 
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1. INTRODUCTION 
Tuberculosis (TB), widely occurring, is still one of the most deadly infectious diseases 
worldwide. Occurrence of tuberculosis along with AIDS has become of greater concern. Current 
treatments of tuberculosis are limited by severe adverse effects of the drugs during long-term 
therapy, potential bioavailability problems associated with drugs, and poor patient compliance. 
Tuberculosis infected with Mycobacterium tuberculosis currently infects approximately one third 
of the world’s population. TB has been declared a public health emergency by the World Health 
organization (WHO). A control programme reaches the WHO targets of 70% case detection and 
85% cure would reduce the incidence rate by 11% (range 8-12) per year and the death rate by 
12% (9-13) per year. Without greater effort to control tuberculosis, the annual incidence of the 
disease is expected to increase by 41% (21-61) between 1998 and 2020 (from 7.4 million to 10.6 
million cases per year). Achievement of WHO targets by 2010 would prevent 23% (15-30) or 48 
million cases by 2020.1 
Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol were earlier prescribed as separate 
formulations in TB control. The emergence of multidrug resistant TB has threatened the efforts 
of TB control. To overcome the treatment failure and increase the patient compliance, the world 
health organization (WHO) and International Union against Tuberculosis and Lung Disease 
(IUATLD) recommended the use of four drug fixed dose combination (FDC). 
The anti-TB drugs have been categorized into two types. Namely, first line and second 
line drugs.First line drugs are rifampicin (RIF) and isoniazid (INH), pyranzinamide (PYZ), 
ethambutol (ETB) and streptomycin daily for 2 months which is known as intensive phase. A 
continuation phase of rifampicin and isoniazid for further 4 months, either daily or 3 times per 
week,to be administered.Second line drugs include capreomycin, anamycin, ethionamide, Para-
amino salicylic acid, cyclosporine, thiacetazone, ciprofloxacin, levofloxacin, Ofloxacin, and 
sparfloxacin.2 
Rifampicin (RIF) is a semi synthetic macrocyclic antibiotic derived from 
streptomycesmediterranei .3key sterilizing component of highly effective short course 
antituberculous regimens and has a unique role in the killing of semi-dormant tubercle bacilli.4 
Rifampicin (rifampicin) is a bactericidal for Mycobacterium tuberculosis. 
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It inhibits mycobacterial DNA-dependent RNA polymerase synthesis by blocking RNA 
transcription. Most strains of M. tuberculosis are inhibited in-vitro by rifampin concentrations of 
0.5µg/ml. Rifampicin is known to include cytochrome P450 activity. 
INH eradicates most of the rapidly replicating bacilli in the first 2 weeks of treatment, 
together with streptomycin and ETB. Thereafter, RIF and PYZ have an important role in the 
sterilization of lesions by eradicating organisms; these two drugs are crucial for successful 6-
month treatment regimens. RIF kills low or non-replicating organisms and the high sterilizing 
effect of PYZ serves to act on semi dormant bacilli not affected by any other anti-TB agent in 
sites hostile to the penetration and action of the other drugs.6,7 INH and RIF, the two most potent 
anti-TB drugs, kill more than 99% of tubercular bacilli within 2 months of initiation of 
therapy.8,9 Using these drugs in conjunction with each other reduces anti-TB therapy from 18 
months to 6 months. 
 After oral administration on an empty stomach, the absorption of rifampicin (rifampin) is 
rapid and practically complete. With a single 600mg dose, peak serum concentration of the order 
of 10microgram/ml generally occurs 2 hours after administration. Food and antacids can 
decrease the oral absorption of rifampicin.10The half-life of rifampicin for this dose level is of the 
order of 2.5 hours.11 It is 75% bound to plasma proteins and it is metabolized in the liver to an 
active metabolite, deacetylrifampin and undergoes enterohepatic recycling. A mean RIF maximal 
serum concentration (Cmax) of 10.54 ± 3.18 µg/ml, the time at which it occurred (Tmax) of 2.42 ± 
1.32 h, and the area under the curve from time zero to infinity (AUC0–∞) of 57.15 ± 13.41 
µg.h.ml-1 on fasting conditions.12 The previous studies indicate that rifampicin alone was 
degraded by 12.4% in an acidic medium in 1hr to 3-formylrifamycin and in the presence of 
isoniazid the degradation increased to 21.5% and also indicated that the degradation of 
rifampicin to 3-formylrifamycin is almost more than two times faster in the presence of isoniazid 
than that of rifampicin alone.13 
Bioavailability of rifampicin is significantly impaired when it is administered along with 
isoniazid as a fixed dose combination, in comparison with administration of formulation 
containing only rifampicin. This lends confirmation to earlier in-vitro studies indicating isoniazid 
accelerates degradation of rifampicin into its insoluble,poorly absorbed derivative in acidic 
environment of stomach. There exists a qualitative correlation between acceleration of in-vitro 
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degradation of rifampicin in presence of isoniazid in acidic medium and decrease in the in-vivo 
bioavailability of rifampicin when administered as combination formulation with isoniazid. 
It has been reported that reduced bioavailability of rifampicin from rifampicin-isoniazid 
fixed dose combination formulations may be one of the factors responsible for development of 
resistance to rifampicin.Thus, there is a need to develop stable formulations containing 
rifampicin-isoniazid combination to withstand the acidic environment of stomach. 
Among the various polymers used in drug delivery research ,PLGA(poly-d ,l- lactide -co- 
glycolide)is one of the most successfully used biodegradable nanosystem for the development of 
nanomedicines since it undergoes hydrolysis in the body to produce the biodegradable metabolite 
monomers , lactic acid and glycolic acid. Since the body can effectively deal with these two 
monomers, there is very minimal systemic toxicity associated with this polymer.  
Drugs do not deliver themselves. For a molecule to reach the target site from the site of 
administration in sufficient concentration, and to maintain therapeutic levels for a sufficient 
period of time, a delivery system is needed. The delivery system is as important as the 
therapeutic moiety itself. Controlled and novel drug delivery, which was only a dream or at bests 
a possibility, is now a reality. During last decade and half, pharmaceutical and other scientist 
have carried out extensive and intensive investigation in the field of drug research. Among those, 
nanoparticulte drug delivery systems from biodegradable and biocompatible polymer are 
interesting option for controlled drug delivery and drug targeting. Poly (lactide-co- glycolide) 
has gained attention for preparation of wide variety of delivery systems containing several drugs 
due to their biodegradable and biocompatible properties and low toxicity.Because of their 
biodegradability and biocompatibility, Polylactic acid and its copolymers with glycolic 
acid(PLGA) are widely employed for the preparation of sustained release preparations3 and 
PLGA microparticles have successfully employed as Antitubercular drug (ATD) carrier 4-7. 
With injectable PLGA microparticle a sustained drug release has been observed for 6-7 weeks in 
mice4-5. The formulation was subsequently explored as an ATD-carrier in order to avoid the 
discomfort associated with subcutaneous injection. However, oral PLGA microparticle suffered 
from several drawbacks such as low drug encapsulation, high polymer composition, sustained 
drug release for 3-4 days6 and a partial therapeutic benefit. It is possible to circumvent these 
drawbacks by developing PLGA nanoparticles (PLGA-NP) encapsulated three front line 
antitubercular drugs, i.e. rifampicin (RIF), isoniazid (INH) and pyrazinamide (PZA) which 
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resulted in a reduced dosing frequency in a murine TB model. The administration routes of 
PLGA nano / micro particle may vary from parenteral, oral, dermatological, pulmonary and nasal 
to ocular.Recently, diclofenac sodium-loaded PLGA nanoparticles were developed for ocular use 
and found good biocompatibility with eye. Sparfloxcin loaded PLGA (50:50) nanoparticles were 
also studied extensively in various pharmacological aspects for their application in treatment of 
conjunctivitis and proved to have good stability and ocular tolerance. Tuberculosis (TB), a 
ubiquitous, high contagiouschronic granulomatous bacterial infection caused by the 
Mycobacterium tuberculosis that infects over 8 million people worldwide and is responsible for 
2 million deaths annually. Although an effective therapeutic regimen is available, patient 
noncompliance (because of the need to take antitubercular drugs (ATDs) daily or several times a 
week) results in treatment failure as well as the emergence of drug resistance. The study also 
reveals that fabrication of a polymeric once-daily oral multiparticulate fixed dose combination of 
the principal antitubercular drugs, which attains segregated delivery of rifampicin and isoniazid 
for improved rifampicin bioavailability,could be a step in the right direction in addressing issues 
of treatment failure due to patient noncompliance. 
Patient compliance can be improved by the use of ATD formulations, which reduce the 
dosing frequency of the drugs. Thus the purpose of the present study was to prepare Rifampicin 
loaded PLGA nanoparticles for improveing bioavilability of rifampicin plga nanoparticles from 
fixed dose combination with isoniazid,pyrazinamide and etambutal.14  
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2. REVIEW OF LITERATURE 
2.1. Epidemology of TB 
TB is an infection caused by M. Tuberculosis. The highest prevalence of tuberculosis 
infection and estimated annual risk of tuberculosis infection are in sub-Saharan Africa and 
Southeast Asia.15 Mycobacterium africanum consists of two phylogenetically distinct lineages 
within the Mycobacterium tuberculosis complex, known as M. africanum West African 1 and M. 
africanum West African 2. These lineages are restricted to West Africa, where they cause up to 
half of human pulmonary tuberculosis.16  
The incidence of tuberculosis is stable and HIV-1 absent, a control programme reaches 
the WHO targets of 70% case detection and 85% cure would reduce the incidence rate by 11% 
(range 8-12) per year and the death rate by 12% (9-13) per year. Without greater effort to control 
tuberculosis, the annual incidence of the disease is expected to increase by 41% (21-61) between 
1998 and 2020 (from 7.4 million to 10.6 million cases per year). Achievement of WHO targets 
by 2010 would prevent 23% (15-30) or 48 million cases by 2020.17 
India is classified along with the sub-Saharan African countries to be among those with a high 
burden and the least prospects of a favourable time trend of the disease as of now (Group IV 
countries). The average prevalence of all forms of tuberculosis in India is estimated to be 5.05 
per thousand, prevalence of smear-positive cases 2.27 per thousand and average annual incidence 
of smear-positive cases at 84 per 1,00,000 annually.18 
The human immunodeficiency virus (HIV) epidemic is causing increases in the number 
of tuberculosis cases, particularly in Africa, although increases are also expected in Southeast 
Asia. In many industrialized countries, TB has recently failed to decline, and in eastern Europe 
and the former Soviet Union, cases and deaths are increasing. Drug resistance is a serious 
problem, especially in the United States.1 TB remains a major cause of morbidity and mortality 
worldwide in the 21st Century. The WHO and other organizations have put vast resources into 
studying the disease, as well as implementing and monitoring treatment. There are large 
disparities between the rates of TB in children in resource poor countries and those in 
industrialised countries. Factors such as poverty, overcrowding and HIV infection have 
contributed greatly to the resurgence of childhood TB, particularly in Sub-Saharan Africa. The 
mortality rates from TB in children from resource-poor counties are unacceptably high. While 
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there are many challenges in the diagnosis and treatment of TB in children, perhaps the greatest 
challenge globally is to begin to identify the extent of disease in this forgotten group.19 
TB remains prominent in international statistics of ill health mainly because it kills young adults. 
More than 80% of the burden of tuberculosis, as measured in terms of disability-adjusted life 
years (DALYs) lost, is due to premature death rather than illness. About 1·7 million people died 
of tuberculosis in 2004, including 264 000 patients who were co infected with HIV.20 
Effective control of tuberculosis (TB) requires an understanding of the changing 
epidemiology of the disease. The success in reducing the tuberculosis burden reflects several 
factors, including improved public health efforts, physician and patient education, infection 
control measures, and the use of directly observed therapy (DOT). Future efforts to curtail the 
incidence of TB will require vigilant public health efforts, improving education of patients and 
health care personnel, identifying mechanisms and routes of transmission, and assuring adequate 
treatment and prophylactic regimens among infected individuals.21 
2.2. Drug therapy in TB 
TB therapy is a multi-drug regimen given over a long period of time. Single agent TB 
therapy rapidly gives rise to drug-resistant organisms. Multi-drug treatment needs to be 
prolonged because mycobacterium tuberculosis it divides slowly and becoming drug insensitive. 
The advent of rifampicin and pyrazinamide allowed highly effective ‘short course’ TB Regimes 
usually a two-month intensive phase with rifampicin (R), isoniazid (H), pyrazinamide (Z) and 
ethambutol (E), followed by a four month continuation phase with RH (2RHZE/4RH).22 
INH and RIF, the two most potent anti-TB drugs, kill more than 99% of tubercular bacilli within 
2 months of initiation of therapy. Using these drugs in conjunction with each other reduces anti-
TB therapy from 18 months to 6 months. 23,24 
INH eradicates most of the rapidly replicating bacilli in the first 2 weeks of treatment, together 
with streptomycin and ETB. Thereafter, RIF and PYZ have an important role in the sterilization 
of lesions by eradicating organisms; these two drugs are crucial for successful 6-month treatment 
regimens. RIF kills low or non-replicating organisms and the high sterilizing effect of PYZ 
serves to act on semi dormant bacilli not affected by any other anti-TB agent in sites hostile to 
the penetration and action of the other drugs.25,26 
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2.3. TB drugs in development: 
Pyrrole LL3858: Limited data are available regarding pyrrole LL3858. It is currently 
undergoing phase 1 clinical trials by Lupin Limited (India). Available data suggest that LL3858 
has potency against standard and drug-sensitive TB strains in vitro.27 
Gatifloxacin: Gatifloxacin is a fluoroquinolone that inhibits DNA gyrase, thus inhibiting TB 
DNA replication and transcription. Gatifloxacin is currently undergoing phase 3 clinical trials. 
Gatifloxacin holds the potential to be the first TB agent to reduce pulmonary TB therapy to four-
month duration. There are weak data to support its efficacy against MDR-TB.28 
R207910: R207910 is a diarylquinoline and is also known as Compound J and TMC207. It 
inhibits ATP synthase leading to ATP depletion and pH imbalance. Where it is undergoing phase 
2a clinical trials in both drug sensitive and resistant disease. Murine studies suggest that 
R207910 has a good safety and tolerability profile and potent early bactericidal activity, 
matching isoniazid. It had a synergistic effect with pyrazinamide for MDR-TB; R207910/H/Z or 
R207910/R/Z combinations were more effective than amikacin/Z/moxifloxacin/ethionamide 
regimens.29 
OPC-67683: OPC-67683 is a nitroimidazo-oxazole that is similar in structure to PA-824. It 
inhibits cell wall biosynthesis. Otsuka Pharmaceuticals (Japan) are currently conducting phase 2 
clinical trials. Preclinical studies in rodents and dogs suggest that OPC-67683 could be used in 
HIV/AIDS as it has no effect on CYP. It may have treatment-shortening potential as it synergises 
in vitro with rifampicin and pyrazinamide. OPC-67683 is effective against MDR-TB in vitro and 
displayed no cross-resistance to first line TB therapy. It also has potential to treat LTBI.30 
PA-824: PA-824 is a nitroimidazo-oxazine. It requires activation by M. tuberculosis F420 factor 
and inhibits synthesis of cell wall lipids as well as protein synthesis. The TB alliance is currently 
conducting phase 1 clinical trials of PA-824. Preliminary studies suggest that PA-824 will be 
active against MDR-TB and has no cross-resistance with other anti-tubercular drugs. 
Importantly, it is not metabolised by CYP and does not induce or inhibit CYP. It had similar 
bacteriostatic efficacy to rifampicin and was more efficient than isoniazid or moxifloxacin but 
less efficient than rifampicin.31 
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Moxifloxacin: Moxifloxacinis is a fluoroquinolone and has a similar mechanism of action to 
gatifloxacin. It is undergoing phase 2 and 3 clinical trials. Moxifloxacin kills rifampicin-tolerant 
persisters in vitro, and it may help treat MDRTB if co-administerd with ethionamide. It may thus 
shorten duration of TB therapy.32 
SQ-109: SQ-109 is an ethylenediamine and is derived from ethambutol. It is postulated to inhibit 
cell wall biosynthesis and has intracellular targets, which have not yet been elucidated. SQ-109 
appears to be synergistic with isoniazid and rifampicin.33 
2.4. Rifampicin bioavailability 
Rifampicin After oral administration on an empty stomach, the absorption of rifampicin 
(rifampin) is rapid and practically complete. With a single 600mg dose it undergoes first passage 
through the hepatoportal system, peak serum concentration of the order of 10microgram/ml 
generally occurs 2 hours after administration. The half-life of rifampicin for this dose level is of 
the order of 2.5 hours. On repeated administration, and most likely as a consequence of self-
induced (autoinduction). Approximately 80% of rifampicin is transported in blood bound to 
plasma proteins, mainly albumin. Deacetylrifampicin, the more polar metabolic derivative of 
rifampicin, behaves in the opposite way since its rate of transfer into bile is 4 times higher than 
that into urine. The rate of biotransformation of rifampicin into desacetylrifampicin is of the 
same order of magnitude as that of biotransformation of the latter into a further metabolic 
derivative, which could be a glucuronide conjugate.34 
The absolute bioavailability of oral rifampin was determined in 20 pediatric patients. 
Intravenous doses of rifampin (mean 287 mg/m2) were compared with P.O. doses (mean 324 
mg/m2). Pharmacokinetic analysis of the rifampin serum concentration data indicated that only 
50 +/- 22% of a freshly prepared p.o. suspension were absorbed. The rifampicin elimination half-
life following i.v. administration (2.25 +/- 0.64 h) was not different from that observed following 
p.o. dose administration (2.61 +/- 1.35 h). Peak rifampin concentrations were significantly higher 
following i.v. administration when corrected to a 300 mg/m2 dose (27.4 vs. 9.1 [mu]g/ml, 
respectively, P < 0.0001) than after P.o administration. The peak concentration following a p.o. 
dose occurred at 2.0 +/- 0.9 h. The ratios of desacetylrifampicin to rifampin areas under the 
curves were similar for i.v. and p.o. routes of administration (0.23 vs. 0.19), suggesting linear 
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metabolism of rifampin to this metabolite. 3-formylrifamycin SV concentrations were lower than 
those of desacetylrifampicin and were detectable in less than half of the patients.35  
 
The problem with rifampicin is its poor/variable bioavailability of rifampicin in anti-
tubercular fixed-dose combination (FDC) products. They determined that rifampicin 
decomposition is enhanced by the presence of isoniazid in stomach after ingestion. 80–90% of 
rifampicin was dissolved in 0.1 M HCl within 10 min, and all samples showed an overlapping 
dissolution profile.36 
comparative bioavailability of rifampicin (RIF) after administration of a single 
component RIF (450 mg) capsule and rifampicin-isoniazid (RIF-INH) (450+300 mg) fixed dose 
combination (FDC)capsule formulations. Six healthy male volunteers participated in a single 
dose, two treatment, two period, cross-overstudy. A sensitive, specific and accurate HPTLC 
method was developed, validated and employed for estimation of RIF and its major active 
metabolite, 25-Desacetylrifampicin (25-DAR) levels, in urine. Using the urinary excretion data 
various pharmacokinetic parameters:AUC 0-24, AUC0-∞ cumulative amount excreted in 24 h, 
peak excretion rate, etc. for both RIF and 25-DAR were calculated and compared statistically 
(ANOVA, 90% confidence interval for ratio). Significant decrease in the bioavailability of RIF 
from FDC capsules was observed. The present bioavailability study confirms our serious doubts 
about the stability of RIF in presence of INH in acidic environment of stomach, which probably 
is the main factor responsible for the reduced bioavailability of RIF from RIF-INH combination 
formulations. This study underlines the fact that there is an urgent need to reconsider the 
formulation of the FDC product in order to minimize or avoid the decomposition of RIF in 
gastrointestinal tract.37 
 
The problem of poor/variable bioavailability of rifampicin, which is shown in particular 
when the drugs are present in anti-tubercular fixed-dose combination (FDC) products. There is a 
potential of failure of therapy in patients. Some simple solutions offered by the knowledge of the 
cause were discussed and concluded that there is a need to have a multifaceted approach to 
handle the problem.38 
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2.5. Degradation of rifampicin 
 
Degradation of rifampicin in 0.1N HCl, and simulated gastric fluid (SGF) at 37°C in 45 
min (USP dissolution test conditions) in the absence and presence of isoniazid has been 
documented. Rifampicin alone decomposes in the described conditions to an average extent of 
6.33%, while the loss of rifampicin in the presence of isoniazid increases on an average to 
16.32%.39,40 
 
The extent of decomposition of rifampicin in the presence of isoniazid in pH range of 1-3 
at 37° C in 50 min, the mean stomach residence time. Its showed that rifampicin degraded in the 
presence of isoniazid to a higher extent at pH 2, the maximum pH in the fasting condition, under 
which antituberculosis fixed dose combination (FDC) products are administered. The extent of 
decomposition was also determined in marketed products, and the value range from 13-35% for 
rifampicin. This emphasizes that antituberculosis FDC formulations, which contain both drugs, 
should be designed in a manner that the interaction of the two drugs is prevented when the 
formulation are administered on an empty stomach.40 
 
Rifampicin is well absorbed from the stomach due to its solubility, which is maximum 
between pH 1-2. Isoniazid is poorly absorbed from the stomach, but is well absorbed from all 
three segments of the intestine. In combination, rifampicin disappearance was enhanced in the 
presence of isoniazid in the stomach and jejunum, but isoniazid disappearance was not 
influenced by rifampicin. The study shows higher in situ rifampicin disappearance in the 
presence of isoniazid, attributable to drug degradation due to catalysis by isoniazid. As the two 
drugs show regional specific permeability, FDCs without reduced rifampicin bioavailability 
resulting from its decomposition in the presence of isoniazid can be designed by segregating 
delivery of the two drugs by around 3-4 h. Rifampicin should be released in the stomach and 
isoniazid in the intestine.41 
 
Rifampicin is better absorbed through the stomach and duodenum than through the distal 
regions of the intestine. Rifampicin alone exhibited decomposition of ~4% at pH 2, whereas it 
was negligible at pH 5.5 and 7. Rifampicin showed similar decomposition pattern even in the 
presence of Nucleotide/Nucleoside Reverse Transcriptase Inhibitors (NRTIs).42 
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2.6. Nanoparticles as drug delivery systems 
Over the last few decades, the applications of nanotechnology in medicine have been 
extensively explored in many medical areas, especially in drug delivery. Nanotechnology 
concerns the understanding and control of matters in the 1- 100 nm range, at which scale 
materials have unique physicochemical properties including ultra small size, large surface to 
mass ratio, high reactivity and unique interactions with biological systems. By loading drugs into 
nanoparticles through physical encapsulation, adsorption, or chemical conjugation, the 
pharmacokinetics and therapeutic index of the drugs can be significantly improved in contrast to 
the free drug counterparts.  
Many advantages of nanoparticle-based drug delivery have been recognized, including 
improved serum solubility of the drugs, prolonging the systemic circulation lifetime, releasing 
drugs at a sustained and controlled manner, preferentially delivering drugs to the tissues and cells 
of interest, and concurrently delivering multiple therapeutic agents to the same cells for 
combination therapy. Moreover, drug-loaded nanoparticles can enter host cells  through 
endocytosis and then release drug payloads to treat microbes-induced intracellular infections. As 
a result, a number of nanoparticle-based drug delivery systems have been approved for clinical 
uses to treat a variety of diseases and many other therapeutic nanoparticle formulations are 
currently under various stages of clinical tests. 
Mechanisms of Nanoparticle - Based Antimicrobial Drug Delivery to Microorganisms 
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`Fig.  (a) nanoparticles fuse with microbial cell wall or membrane and release the carried drugs 
within the cell wall or membrane; (b) nanoparticles bind to cell wall and serve as a drug depot to 
continuously release drug molecules, which will diffuse into the interior of the microorganisms.45 
         These nanocarriers are sub micron particles containing entrapped drugs intended for enteral 
or parenteral administration which might prevent or minimize the drug degradation and 
metabolism as well as cellular efflux. Nanoparticles also have a long shelf life, are made of safe 
materials, including synthetic biodegradable polymers, natural biopolymers, lipids and 
polysaccharides and have the potential for overcoming important mucosal barriers, such as 
intestinal, nasal and ocular barriers. 43 
2.7. Polymers as drug delivery vehicle 
  A number of polymers have been investigated for formulating biodegradable 
nanoparticles, such as polylactide (PLA), polycaprolactone(PCL) and poly(lactide-co-glycolide) 
(PLGA). These are biocompatible and biodegradable polymers which have recently been the 
subject of extensive investigation. However, due to copolymer crystallization, low 
biodegradation rate or poor flexibility,the application of polymer  nanoparticles is limited. For 
example,in case of homopolymer poly(L-lactide), due to its crystalline and low biodegradation 
rate, drug release from relevant drug delivery devices is mainly controlled by drug diffusion 
similar to that in non-degradable drug carriers. Biodegradation of polymeric biomaterials 
involves cleavage of hydrolytically or enzymatically sensitive bonds in a polymer, leading to 
polymer erosion. Depending on the mode of degradation, polymeric biomaterials can be further 
classified into hydrolytically degradable polymers and enzymatically degradable polymers. The 
most part of naturally occurring polymers undergo enzymatic degradation. Biodegradation of 
hydrolysable polymers proceeds in a diffuse manner, with amorphous regions degrading prior to 
the complete split of crystalline and cross-linked regions. Factors affecting biodegradation of 
polymers might be: chemical structure, chemical composition, distribution of repeat units in 
multimers, presence of ionic groups, presence of unexpected units or chain defects, 
Configuration structure, molecular weight, molecular weight distribution, morphology 
(amorphous/semicrystalline, microstructures, residual stresses), presence of low molecular-
weight compounds, processing conditions ,annealing, sterilization process, storage history, 
shape, site ofimplantation, adsorbed and absorbed compounds (water, lipids,ions, etc.), 
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physicochemical factors (ion exchange, ionic strength pH), physical factors (shape and size 
changes, variations of diffusion coefficients, mechanical stresses, stress-and solvent-induced 
cracking, etc.), mechanism of hydrolysis (enzymes versus water). 
Structure, properties and applications of nanoparticles are strongly affected by the 
properties of the polymer used in their formulation. For each application, one must evaluate the 
properties of the system (drug and particle) and determine the optimal formulation for a given 
drug delivery application. Polyesters based on polylactide (PLA), polyglycolide (PGA), 
polycaprolactone (PCL), and their copolymers have been extensively employed as systems for 
drug delivery. PLGA and PLA have been approved by the FDA for numerous clinical 
applications, such as sutures, bone plates, abdominal mesh, and extended-release 
pharmaceuticals. 
Biomedical uses of PLA have been reported since the 1960s. Tissue response to such 
biodegradable materials is characterized by minimal localized inflammation and foreign body 
reaction that lessen with time. No toxic effects have been associated with the use of such 
polymers, biodegraded via a random, non-enzymatic process into homopolymers of lactic acid 
and glycolic acid, known products of cellular intermediary metabolism. PLGA degradesthrough 
hydrolysis of its ester linkages in the presence of water. It has been shown that the time required 
for the degradation of PLGA is related to the ratio of monomers used in its production: the 
higher the content of glycolide units, the lower the time required for degradation. An exception 
to this rule is copolymer with 50:50 ratios of monomers, which undergoes faster degradation 
(about two months) in both in vitro and in vivo conditions. Miller et al. have shown that PLGA 
50:50 is the fastest degrading composition, with the degradation rate being decreased when either 
lactide or glycolide content of the copolymer was increased. 44 
2.8. Pharmaceutical approaches for the treatment of TB 
Chemotherapy of TB is complicated by the need of multidrug regimens that need to be 
administered over long periods. Poor patient compliance is the single most common reason for 
chemotherapy failure in TB.46 To minimize toxicity and improve patient’s compliance, extensive 
progressive efforts have been made to develop various implant, micro particulate, and various 
other carrier-based drug delivery systems to either target the site of M. tuberculosis infection or 
reduce the dosing frequency, which forms an important therapeutic strategy to improve patient 
outcomes.47,48 The systems under discussion employ either biodegradable polymers or systems 
15 
 
requiring removal after use, and can release the drug either by membrane or matrix-controlled 
diffusion.  
Recent trends in controlled drug delivery have seen micro encapsulation of 
pharmaceutical substances in biodegradable polymers as an emerging technology. Carrier or 
delivery systems such as liposomes and microspheres have been developed for the sustained 
delivery of anti-TB drugs and have demonstrated better chemotherapeutic efficacy when 
investigated in animal models (e.g. mice)2. Anti-TB drugs have been successfully entrapped and 
delivered in biodegradable polymers such as poly (DL-lactide-co-glycoside) (PLG), which are 
biocompatible and release drug in a controlled manner at therapeutic levels.48 
Dutt and Khuller (2001) 49 have entrapped INH and RIF in PLG polymers. When injected 
subcutaneously as a single dose, the micro particles, having a diameter ranging from 11.75 µm to 
71.95 µm, provided sustained release of drugs over 6–7 weeks when tested in mice. The authors 
previously observed that particles with a size range >10 µm remained at the site of injection 
forming a depot. The entrapped contents of the micro particles were gradually released by 
diffusion through the polymeric particles. Such depots can show release profiles extending over 
several months culminating in degradation of the entire polymeric device. However, these 
formulations have to be injected either subcutaneously or intravenously, and the pain and 
discomfort associated with these routes of administration, in general, is often not acceptable. 
Hence, there is a continuous need to develop an oral drug delivery system that is convenient for 
patients.49 
Amidst these concerns, Ain et al (2002)50 reported the pharmacokinetics of PLG 
encapsulated anti-TB drugs; orally administered either individually or in combination in mice. A 
study conducted by Pandey et al (2003)51 reported the formulation of three frontline anti-TB 
drugs, i.e. RIF, INH and PYZ encapsulated in PLG nanoparticles. On oral administration of 
drug-loaded nanoparticles to M. tuberculosis-infected mice at every 10th day, no tubercle bacilli 
could be detected in the tissues after 5 oral doses of treatment. Therefore, oral nanoparticle-based 
anti-TB drug therapy can allow for a reduction in dosing frequency for better management of 
TB. 
Osmotically regulated capsular multi-drug oral delivery system comprising asymmetric 
membrane coating- and dense semi permeable membrane coating-capsular systems for the 
simultaneous controlled administration of RIF and INH for the treatment of TB. This was in an 
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attempt to reduce the problems associated with multidrug therapy. The modified asymmetric 
system provided satisfactory sustained release of RIF and INH, with an initial burst release that 
may be sufficient to achieve minimum effective concentration in blood. Thereafter, the system 
provided the release of the drugs in a near zero order rate – an ideal release profile for controlled 
drug delivery. In turn, this would improve the safety profile of the drugs and enhance the activity 
duration of drug exhibiting short half-lives. The once daily system is optimal, and could 
potentially enhance patient compliance.46  
Further attempts to solve the problems inherent in multidrug therapy have included the 
development of biodegradable polymeric micro- or nanoparticulate carrier systems to target 
alveolar macrophages that harbour M.tuberculosis. In the case of pulmonary TB, delivering the 
drug directly to the site of infection through inhalation of an aerosolised delivery system has the 
inherent advantages of bypassing first-pass metabolism and maintaining local therapeutically 
effective concentrations with decreased systemic side effects.52 Because M. tuberculosis is   
known to infect alveolar macrophages and affect the pathogenesis of TB, there have been 
renewed interests in targeting of anti-TB drugs to these cells. Despite the success of these 
systems in targeting and providing sustained release of anti-TB drugs to alveolar macrophages, 
the methods used to generate particles in these studies vary in their capability for the production 
of reproducible particles with the optimal size for inhalation therapy (i.e. <5µm).  
Barrow et al (1998)53 formulated RIF-loaded microspheres using the method of solvent 
evaporation, aiming to maintain a size of 1 to 10-µm. Only the size distributions of two 
formulations were reported, being 3 to 4 µm and distribution demonstrated a Gaussian curve.   
Dutt and Khuller ( 2001)49 encapsulated INH and RIF into hardened PLG micro particles 
by a double emulsification solvent evaporation procedure, and these had a resultant volume mean 
diameter of 11.75 µm for INH microparticles and 11.64 µm for RIF microparticles. These are 
currently undergoing Phase I trials. Sharma et al (2001)54 incorporated both INH and RIF into 
PLG microspheres using a combination of solvent extraction and evaporation, but these particles 
had a mean diameter of 6.214 µm and only 38% of the microspheres fell in the size range of 0.5–
3 µm. Suarezet et al (2001)55 attained the airway delivery of RIF microparticle shaving volume 
median diameters of 2.76 ± 1.57µm. O'Hara and Hickey56 succeeded in obtaining RIF loaded 
PLG particles with median diameters by volume of 2.76 µm and 3.45 µm by spray drying and 
solvent evaporation respectively. Zhou et al (2005)51 did achieve the formulation of spherical 
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micro particles between 1 and 3 µm in diameter. The microparticles, prepared by the 
precipitation with a compressed anti solvent process, were evaluated for their potential in 
targeting an ionizable prodrug of INH, isoniazid methane sulfonate (INHMS), for sustained 
delivery of INH to alveolar macrophages. 
Most recently Zahoor et al (2006)57 undertook pharmacokinetic and chemotherapeutic 
studies with aerosolized alginate nanoparticles encapsulating INH, RIF and PZA and RIF, INH, 
PYZ, ETB. The nanoparticles were prepared by cation-induced gelification of alginate and were 
235.5± 0 nm in size, with drug encapsulation efficiencies of 70–90% for INH and PZA and 80–
90% for RIF and 88–95% for EMB. The majority of particles (80.5%) were in the respirable 
range, with a mass median aerodynamic diameter of 1.1 ± 0.4 µm and geometric standard 
deviation of1.71 ± 0.1 µm. The chemotherapeutic efficacy of three doses of drug-loaded alginate 
nanoparticles nebulised 15days apart was comparable with 45 daily doses of oral free drugs. 
Thus, inhalable alginate nanoparticles could potentially serve as an ideal carrier for the 
controlled release of anti-TB drugs. Clinical trials are envisaged in the future for evaluation of 
this system before use in humans.  
Pandey and Khuller58 evaluated the chemotherapeutic potential of nebulised solid lipid 
nanoparticles (SLNs) incorporating RIF, INH and PYZ against experimental TB. SLNs are 
nanocrystalline suspensions in water, prepared from lipids, which are solid at room temperature. 
The SLNs, prepared by the emulsion solvent diffusion technique, possessed a favourable mass 
median aerodynamic diameter suitable for broncho alveolar drug delivery. Following a single 
nebulisation to guinea pigs, therapeutic drug concentrations were maintained in the plasma for 
5days and in the organs for 7 days whereas free drugs were cleared after 1–2 days. 
Vyas59 formulated aerosolized liposomes incorporating RIF via a cast-film method employing 
egg phosphatidylcholine- and cholesterol based liposomes. Liposomes coated with alveolar 
macrophage-specific ligands demonstrated preferential accumulation in alveolar macrophages, 
maintaining high concentrations of RIF in the lungs even after 24 hours. 
In another approach to solve the predicament of poor patient compliance, depot-delivery 
of anti-TB drugs has been investigated. Studies have demonstrated that a single implant of INH 
in polylactic-co-glycolic acid (PLGA) copolymer could ensure sustained levels of free INH for a 
period of up to 8 weeks following implantation in rabbits48.  
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2.9. Background of the study 
The literature survey thus reveals the importance of fixed dose combination of 
Rifampicin, Isoniazid, Pyrazinamide and Ethambutol in the treatment of TB to overcome the 
drug resistance and to improve the patient compliances.  Rifampicin appears to be the best choice 
for the treatment of TB however it has poor bioavailability from FDC formulation following oral 
administration due to degradation in the stomach. Rifampicin is well absorbed in the pH range 1-
2 even though it undergoes degradation in the acidic medium and the degradation of  rifampicin 
increases in the presence of Isoniazid ,Pyrazinamide ,Ethambutol and thus affects bioavailability 
of Rifampicin. Development of any method that can stabilize Rifampicin against degradation in 
the stomach will be therapeutically beneficial. 
Since nanoparticles are known to cross the intestinal permeability barriers directly via 
trancellular/ paracellular pathways. It offers better delivery of the encapsulated drug into the 
circulation. In this case they are expected to penetrate inside the infected cell, Where TB is an 
intracellular infection. From the literature study it was found that PLGA is one of the most 
successfully used biodegradable nanosystem for the development of nanomedicine since it 
undergoes hydrolysis in the body to produce the biodegradable metabolite monmers lactic acid 
and glycolic acid. Based on this consideration the present study attempted to improve the 
bioavilability of rifampicin –PLGA nanoparticles from fixed dose combination with isoniazid, 
pyrazinamide and ethambutol. 
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 3. DRUG PROFILE 
3.1. Rifampicin: 
 
Rifampicin is a bactericidal antibiotic drug of the rifamycin group. It is a semisynthetic 
compound derived from Amycolatopsis rifamycinica (formerly known as Amycolatopsis 
mediterranei and Streptomyces mediterranei).  
Structure 
 
 
                                                    Rifampicin 
 
Empirical formula  : C43H58N4O12  
Molecular weight  :822.94. 
Chemical name  :3-[[(4-methyl-1-piperazinyl)imino]methyl]-.5,6,9,17,19,21-
Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1-
piperazinyl)formimidoyl]-2,7(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11-
(2H)-dione 21-acetate [13292-46-1]. 
Physical and Chemical Properties 
Appearance   : orange-red powder  
Melting point   : 183-188°C 
Solubility   : Soluble in dilute acid solutions, slightly soluble in water.  
Rifampicin: Mechanism of Action and Resistance60 
 
Rifampicin specifically inhibits bacterial RNA polymerase, the enzyme responsible for 
DNA transcription, by forming a stable drug-enzyme complex with a binding constant of 10-9 M 
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at 37oC. Various steps involved in transcription of bacteria is inhibited when rifampicin 
interferes with RNA polymerase. The various steps in the process of transcription of DNA to 
RNA are (1) binding of the enzyme to DNA; (2) binding of the first nucleoside tri-phosphate to 
the enzyme-DNA complex; (3) formation of the first phosphodiester bond, leading to a 
dinucleotide (chain initiation); (4) assembly of more nucleotides to form a polyribonucleotide 
(chain elongation); and (5) release of the completed RNA chain from the template (chain 
termination). More specifically, the β subunit of this complex enzyme is the site of action of 
drug. The corresponding mammalian enzymes are not affected by rifampicin. 
Bacterial resistance to rifampicin is caused by mutations leading to a change in the 
structure of the β subunit of RNA polymerase. Such resistance is not an all-or nothing 
phenomenon; rather, a large number of RNA polymerases with various degrees of sensitivity to 
rifampicin have been found. No strict correlation exists between enzyme sensitivity and MIC 
values, since inhibition of RNA synthesis does not always show up to the same extent in the two 
different test systems used for the determination of these values. 
 
 
 
 
 
21 
 
Mechanism of action of rifampicin on mycobacterium tuberculosis 
Formulations of rifampicin in market 
Monocomponent products 
           Rifampicin capsules of 150 mg, 300 mg, 450 mg, 600 mg            
Combination Products  
Dipicin :   Isoniazid 150 mg, Rifampicin 300 mg                   
Pyrina :   Isoniazid 150 mg, Rifampicin 150 mg,  
                 Pyrazinamide 500 mg 
Rambuto:   Isoniazid 200 mg, EthambutolHCl 400 mg, 
     Rifampicin 300 mg, Pyridoxine 25 mg 
Rimactazid:   Isoniazid 100 mg Rifampicin 150  
       Isoniazid 200 mg Rifampicin 225  
       Isoniazid 150 mg Rifampicin 300    
Routes of entry 
 Oral         : This is the common route of entry. 
 Inhalation : Not applicable. 
 Dermal     : Not applicable 
 Eye          : Use for ocular Chlamydia infection treatment  
 Parenteral  : Rifampicin may be given intravenously. 
 Pharmacokinetics 
Absorption: Rifampicin is readily absorbed from the gastrointestinal tract (90%).  Peak plasma 
concentration occurs at 1.5 to 4 hours after an oral dose.  After a 450 mg oral dose, plasma levels 
reach 6 to 9 µg/ml while a 600 mg dose on an empty stomach yields 4 to 32 µg/ml (mean 7 
µg/ml).     
Distribution: It is widely distributed in body tissues and fluids. 89% of rifampicin in circulation 
is bound to plasma proteins.61It is lipid soluble. When the meanings are inflamed, rifampicin 
enters the cerebrospinal fluid (4.0 µg/ml after a 600 mg oral dose). It reaches therapeutic levels 
in the lungs, bronchial secretions, pleural fluid, other cavity fluid, liver, bile, and urine.62 
Rifampicin has a high degree of placental transfer with a foetal to maternal serum level ratio of 
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0.3.  It is distributed into breastmilk.63The apparent volume of distribution (VD) is 0.93 to 1.6 
L/kg.64 
Biological half-life by route of exposure: T1/2 = three hours range (2 to 5 hours).  
Metabolism: Approximately 85% of rifampicin is metabolized by the liver microsomal enzymes 
to its main and active metabolite - deacetylrifampicin. Rifampicin undergoes enterohepatic 
recirculation but not the deacetylated form.  Rifampicin increases its own rate of metabolism. 
Rifampicin may also be inactivated in other parts of the body. Formylrifampicin is a urinary 
metabolite that spontaneously forms in the urine.  
Elimination by route of exposure: Rifampicin metabolite deacetylrifampicin is excreted in the 
bile and also in the urine.  Approximately 50% of the rifampicin dose is eliminated within 24 
hours and 6 to 30% of the drug is excreted unchanged in the urine, while 15% is excreted as 
active metabolite. Approximately 43 to 60% of oral dose is excreted in the faeces.62Intrinsic total 
body clearance is 3.5 (+/- 1.6) ml/min/kg, reduced in kidney failure.61 Renal clearance is 8.7 
ml/min/kg. Rifampicin is excreted in breast milk (1 to 3µg/ml).  
Interactions 
1. Food lowers peak blood levels because of interference with absorption of rifampicin.  
2. Antacids containing aluminium hydroxide reduced the bioavailability of rifampicin.  
3. Para-amino salicylic acid granules may delay rifampicin absorption. These two drugs 
should be given 8 to 12 hours apart.62 
4. Isoniazid and rifampicin interaction has led to hepatotoxicity.   
5. Alcohol intake with rifampicin increases the risk for hepatotoxicity.  
6. Rifampicin induces microsomal enzymes of the liver and therefore accelerates 
metabolism of some drugs, e.g.  beta blockers, oral contraceptive pills etc.,            
7. When rifampicin and oral contraceptives are used concomitantly, there is decreased 
effectiveness of oral contraceptives. It was reported that rifampicin may be the cause of 
some menstrual disorders when used with oral contraceptive pills. 
8. Rifampicin can lower the plasma calciferol (Vitamin D) level because of induction of 
enzyme activity. 
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9. Barbiturates and salicylates decrease the activity of rifampicin. 
10. Effects with clofazimine range from no effect to decrease in the rate of absorption of 
rifampicin, delay in the time it reaches peak plasma concentrations decrease in plasma 
rifampicin concentrations.  
Adverse Effects  
1. Severe gastrointestinal side-effects (e.g.pseudomembranouscolitis). 
2. Hypersensitivity,shock shortness of breath, acute haemolyticanaemia, renal failure 
(nephrotoxicity). 
3. The other adverse effects are staining of body fluids, rash, chills and fever, nausea and 
vomiting, arthralgia, diarrhoea, and peripheral neuritis.  
4. Ocular side effects as a consequent to rifampicin use occur in 5 to 15% of patients. 
5. Angioneuroticoedema, urticaria, purpura, Stevens-Johnson syndrome, exfoliative 
dermatitis or pemphigoid lesions have been reported.  
6. Local ophthalmic use of rifampicin has caused irritation of the eyes which manifests 
transiently as lacrimation, hyperaemia, oedema and ocular pain in Special risks  
Toxicity 
1. Thrombocytopenia 
2. Hemolysis  
3. Renal failure 
4. Flu-like syndrome 
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3.2. ISONIAZID 
Isoniazid was synthesized in 1912 at the German University of Prague by Meyer and 
Mally65 
Structure 
 
 
   Isoniazid 
 
Empirical formulae : C6H7N 
Molecular weight : 137.14 
Chemical name :Isonicotinic acid hydrazide 
Physical and chemical properties  
Appearance : White crystalline powder 
Melting point : 170 - 174 
Dose  : 5mgh/kg body weight daily and 10 mg/kg body weight in thrice  
Weakly treatment 
Solubility   : Freely soluble in water and sparingly soluble in alcohol 66 
Mechanism of action 
Isoniazid kills actively growing tuberculii bacilli by inhibiting the biosynthesis of 
mycolic acid which is the major component of cell wall of mycobacterium tuberculosis.67At 
therapeutic levels isoniazid is bacterial against actively growing intracellular and extracellular 
mycobacterium tuberculosis. 
PHARMACOKONETICS  
Absorption  
 
  
90% of drug gets absorbed upon oral administration and the presence of food reduces the 
absorption. Time to attain peak plasma concentration is about 1 to 2 hours  
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Distribution  
 
Isoniazid is widely distributed to all fluids and tissues including cerebrospinal fluid, 
pleural and ascetic fluids, skin, sputum, muscles and lungs. It crosses the placenta and distributed 
in to breast and milk. Protein binding is very low about 10%. 
Volume of distribution                 :  0.57 to 0.76 L/kg 
Biological Half life:  1-5hours  
Metabolism  
 
Metabolism occurs by liver, isoniazid is acetylated by liver in to active metabolites which 
are excreted in urine. Acetyl isoniazid is further hydrolyzed to isonicotinic acid and acetyl 
hydrazine. Non acetylated isoniazid is excreted unchanged in urine. 
Elimination  
 
5 to 30% of drugs get excreted by renal excretion. Slow acetylaters excrete 25% to 66% 
of dose in urine as isoniazid and rapid acetylaters excrete 5 to 37% of dose in urine. 
Drug interactions 68 
1.
 Concomitant use of acetaminophen and isoniazid cause nephrotoxicity 
2. Alaprozolam administration with isoniazid cause elevated plasma concentrations of alaprozolam 
3. Concomitant isoniazid therapy with BCG vaccine may inhibit efficacy of bcg vaccine 
4. Antacids should not be administered with isoniazid 
5. Administration of isoniazid with cycloserine cause increased CNS adverse effects 
Adverse drug reactions  
1. Peripheral neuropathy 69, seizures 
2. Psychosis, optic neuropathy 70 and metabolic acidosis 
3. Hypocalcemia, scaling and eczema 
4. Memory loss, gynecomastia and vitamin B6 deficiency 
Use : Used in treatment of tuberculosis 
Storage: Should protect from moist and light. Stored at 200C to 250C  
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3.3 PYRAZINAMIDE 
The synthesis of  pyrazonic acid, the active metabolites of pyrazinamide. 
Structure 
 
 
Pyrazinamide 
 
Empirical formulae : C5H5N3O 
Molecular weight : 123.11 
Chemical name : Pyrazine-2-carboximide 
Physical and chemical properties  
Appearance : White crystalline powder 
Melting point : 1900c  
Dose  : Orally 15-30mg/kg once daily 
Solubility   : Sparingly soluble in water 
Mechanism of action 
Pyrazinamide is a synthetic purine analogue of nicotinamide and exhibits in vitro 
bactericidal activity only at acidic pH. Pyrazinamide as aquite active agonis intracellular bacilli 
in the acidic environment of macrophages.because of its action agonist intracellular 
bacilli,heoraganism most likely to responsible relabse,it may play an important role in decreasing 
releases with tuberculosis lesions,it has been hybothesized that there may four different 
population of tubercle bacilli. Due to variables in their environment within the body, this four 
population may different in there metabolism and suspectibility to the antituberculosis drug. This 
group of organisms belived to be killed readily by isoniazid ,rifampicin,and streptomycin when 
used in bactericidal doses. The second group of bacilli is thought to have intermittent spurts of 
metabolic acivity,during which time rifampicin most cabable of killing time. The third group of 
bacilii is thought to be found in acidic environment such has with in macrophages. 
Pyarazinamide should be used only in combination with other antitubercular drug in the 
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treatment M tuberculosis; resistant developed rapidly (with in 6 to 8 weeks) when pyrazinamide 
used alone. 
PHARMACOKONETICS  
Absorption: When given orally drug is completely absorbed from GIT, absorption is not 
infuluenced by food intake. After orally intake of 1500mg of pyrazinamide,is peak level is 
obtained; the time taken to reach peak serum concentration is decreased by antacid 
concentration. 
Distribution: Pyrazinamide has excellent penetration into cerebrospinalfluid ranging from 87 to 
105 of corresponding serum concentration. Drugs is distributed to all fluids.31% drugs binds to 
plasma proteins 
Volume of distribution                 :  0.57 to 0.74 L/kg 
Biological Half life:  9-10hours  
Metabolism: Pyrazinamide is hydrolysed in liver to its major active metabolites,pyrazonic acid 
is further hydroxylated to main excretory product 5- hydroxyl pyrazonic acid. Approximately 1% 
to 14% of drug is excreted as unchanged pyrazinamide. 
Elimination: About 1% to 14% of drug is excreted as unchanged pyrazinamide in 
urine,remaining excreted as metabolites.. 
Drug interactions 
1. Allopurinol increses plasma concentration of pyrazoic acid which is directly responcible for renal 
uratesecreation 
2. Pyrazinamide might antagonistically effect the action of madications that have uricosuric effect 
such as acetyl salicylic acid and probencid. 
3.
 A potentially serious intractionexcist with zidovudine in combination therapy. 
 
Use: Used in treatment of tuberculosis 
Storage: Should be storedin well closed container at controlled room temperature at 15 to 300c 
 
 
 
 
       
             It is an oral human therapeutic agent specipically active against actively growing 
microorganisms 
Structure 
                                             
                                                
 
Empirical formula : C10H24N2O2
Molecular weight : 277.23 
Chemical name : 2, 2(ethylene di amino) di
Physical and chemical properties 
Appearance : White crystalline powder
Melting point : 1990c to 2040c  
Dose  : Orally 15mg/kg once dai
Solubility   : Sparingly soluble in water and alcohol.
Mechanism of action 
Ethambutol diffuses into actively growing mycobacterium tuberculosis such as tubercle bacilli 
ethambutol. Appears to inhibit the synthesis of 1 or more metabolites, thus causing 
of cell metabolism, arrest multiplication and causes cell death.
PHARMACOKONETICS  
Absorption:  Absorption is rapid. Food does in show any effect of absorption,following a 
dosage of 25mg/kg body weight, a peak serum concentration of 4 to 5 mg/ 
to 4 hrsafer administration. 
 
 
 
 
 
Distribution: Ethambutol is distributed to tissues and body fluids exert cerebrospinalfluid. 
About 30% drugs bind plasma protein
Volume of distribution: 1.6 lit/kg
Biological Half life: 3-4hours  
3.4 ETHAMBUTOL 
 
Etambutal 
 
-1- butanoldihydro chloride 
 
 
ly 
 
 
lit is achivedwith in 2 
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Elimination: Ethambutol gets eliminated by kidneys 50 to 90 % of drug excreated as unchanged 
form in urine. And 20 to 22 % get excreated in feces. 80% ethambutol is eliminated by 
glomerular filtration and tubular secreation.  
Drug interactions 
1. Magnesium antacid reduces ethambutolresorptin and lowers and delays repectively Cmax 
and Tmax. 
2.
 Ethionamide and isoniazid combination increases ethambutoloccular toxicity 
 
Use: Used in treatment of tuberculosis 
Storage: Should be storedin well closed container at controlled room temperature   at 15 to 300c. 
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3.5 3-Formyl Rifamycin Sv 
Structure: 
                      
 
 
3-formyl rifamycin sv 
 
Empirical formulae                      : C38H47NO13 
Molecular weight                         : 725.78 
Chemical name                             : 3-formyl rifamycin sv 
Synonyms: Rifamycin AF;3-formylrifamycin;3-formylrifampicinsv;Rifamycin, 3-formyl-;3-
formyl rifamycin sv;11-dioxo-l-21-acetate;3-formylrifamycin sv, bp standard;3- formyl 
rifamycin sv(rifampicin intermediate ) 
Physical and chemical properties  
Appearance                :  White crystalline powder 
Melting point             :  170 - 174 
Dose                           : 5mgh/kg body weight daily and 10 mg/kg body weight in    
                                            Thrice Weakly treatment 
Solubility                  :  Freely soluble in water and sparingly soluble in alcohol 
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3.6 POLYMER PROFILE 
3.6.1 Name of the polymer: PLGA or poly (lactic-co-glycolic acid) 
Structure 
 
Typical properties 
PLGA or poly (lactic-co-glycolic acid) is a copolymer which is used in a host of Food 
and Drug Administration (FDA) approved therapeutic devices, owing to its biodegradability and 
biocompatibility. Depending on the ratio of lactic to glycolide used for the polymerization, 
different forms of PLGA can be obtained. All PLGAs are amorphous rather than crystalline and 
show a glass transition temperature in the range of 400c- 600c. Unlike the homopolymers of lactic 
acid (polylactide) and glycolic acid(polyglycolide) which show poor solubilities, PLGA can be 
dissolved by a wide range of common solvents, including chlorinated solvents, tetrahydrofuran, 
acetone or ethyl acetate.The mechanical strength, swelling behavior, capacity to undergo 
hydrolysis and,subsequently, the biodegradation rate are directly influenced by the crstallinity of 
the PLGA polymer. The resultant crystallinity of the PLGA co- polymer is dependent on the type 
and the molar ratio of the individual monomer components (lactide and glycolide) in the 
copolymer chain. PLGA polymers containing 50:50 ratio of lactic and glycolic acids are 
hydrolyzed much faster than those containing a higher proportion of either of the two 
monomers.PGA is highly crystalline because it lacks the methyl side groups of the PLA. Lactic 
acid is more hydrophobic than glycolic acid and, therefore, lactide-rich PLGA co-polymers are 
less hydrophilic, absorb less water and, subsequently, degrade more slowly. 
32 
 
It has a glass transition temperature (Tg) of 450c and an inherent viscosity of 0.5-0.8mPa. The 
Tgs of the PLGA co-polymers are above the physiological temperature of 370c and hence they 
are normally glassy in nature. Thus, they have a fairly rigid chain structure, which gives them 
significant mechanical strength to be formulated as a degradable device. It has been reported that 
the Tgs of PLGA decrease with the decrease of lactic content in the co-polymer composition 
with decreasing M.W. 
Biodegradation of PLGA 
In both in-vitro and in-vivo, PLGA co-polymer undergoes degradation in an aqueous 
environment (hydrolytic degradation or biodegradation) through cleavage of its backbone ester 
linkages. The polymer chains undergo bulk degradation and the PLGA matrix. It has been 
recorded that the PLGA biodegradation occurs through random hydrolytic chain scissions of the 
swollen polymer. The carboxylic end groups present in the PLGA chains increase in number 
during the biodegradation process as the individual polymer chains are cleaved. These are known 
to catalyze the biodegradation process. It has also been reported that large fragments are 
degraded faster internally and amorphous regions degrade faster than crystalline regions. The 
biodegradation rates of the PLGA co-polymers are dependent on the molar ratio of the lactic and 
glycolic acids in the polymer chain, M.W. of the polymer and the degree of crystallinity. 
Applications 
The possibility to tailor the polymer degradation time by altering the ratio of the 
monomers used during synthesis has made PLGA a common choice in the production of a 
variety of biomedical devices such as : grafts, sutures, implants, prosthetic devices, micro and 
nanoparticles. They are also easy to formulate into various delivery systems for carrying a 
variety of drug classes, such as vaccines, peptides, proteins and micro molecules, which have 
been approved by the Food and Drug administration for drug delivery use.It has been used 
successfully in delivery of amoxicillin in treating listeriosis(treatment of Listeria monocytogenes 
infection).As an example, a commercially available drug delivery device using PLGA is Lupron 
Depot for the treatment of advanced prostate cancer.    
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                                        4. AIM AND OBJECTIVE OF THE STUDY 
The present study aimed to improve the bioavailability of Rifampicin Nanoparticles 
from Fixed Dose Combination with Isoniazid, Pyrazinamide and Ethambutol. 
The following parameters were examined 
1. Pre-formulation studies. 
a. Drug and carrier interaction by FT-IR spectroscopy. 
b. Drug and carrier interaction by Differential Scanning  Calorimetry(DSC) 
2. Preparation of calibration curve for simultaneous estimation of Rifampicin and 3FRSV by 
DW-spectrophotometric method . 
3. Preparation of Rifampicin loaded PLGA nanoparticles by emulsification solvent evaporation 
method. 
4. Evaluation of Rifampicin loaded PLGA nanoparticles 
5. Drug and carrier interaction by FT-IR spectroscopy. 
a. Particle size determination  by Scanning Electron Microscopy(SEM) 
b. Surface characteristic by Zeta potential analyzer 
c. Thermal analysis by Differential Scanning Calorimetry (DSC). 
d. Rifampicin encapsulation efficiency and loading capacity of the nanoparticles. 
e. Invitro release of Rifampicin from the nanoparticles. 
f. Dissolution studies and Diffusion studies 
Based on the conditions of in vitro release best sample was used for in vivo studies in 
animal model. 
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5. PLAN OF WORK 
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35 
 
6.   MATERIALS 
                 The drugs chemicals and equipments were used in the present project work are given 
in tables.Drugs chemicals were of analytical grade and procured either gift samples or purchased. 
6.1. Chemicals  
Chemicals Supplier/Manufacturer 
Rifampicin Themis lab, Mumbai 
3FRSV Themis lab, Mumbai 
Isoniazid,Pyrazinamide and etambutal Cadila health care ltd, ahmedabad 
Chloroform SRL chem, Mumbai 
Methanol SRL chem, Mumbai 
Concentrated hydrochloric acid Ranbaxy Ltd, Vijayawada 
Anhydrous sodium sulphate Samir tech chem, Mapurkur 
Potassium dihydrogen phosphate S.D fine chemicals, Bangalore 
Dibasic sodium phosphate Samir tech chem., Mapurkur 
Acetonitrile(ACN) Samir tech chem, Mapurkur 
Disodium hydrogen phosphate S.D fine chemicals, Bangalore 
Eppendrof’s tube Redcross, Nellore 
PLGA Themis lab, Mumbai 
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 6.2. Equipments 
 
Equipments Model/Company 
Dialysis membrane 110 Himedia laboratory,mumbai 
Auto pipettes Tripette, Merck, Germany 
Analytical balance AG 135, Mettler Toledo 
UV-Visible Spectrophotometer Shimadzu UV-1800, Japan 
DW-Spectrophotometer Shimadzu 160A UV-Vis, japan 
pH meter MA 235, Mettler Toledo 
High performance liquid chromatography Shimadzu CLASS-VP, Japan 
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7.0. METHODS 
7.1. preformulation studies 58,59 
Before formulation of drug substances into a dosage form, it is essential that the drug and 
polymer should be chemically and physically characterized. Preformulation studies give the 
information needed to define the nature of the drug substance and provide a frame work for the 
drug combination with pharmaceutical excipients in the fabrication of a dosage form. 
Fourier Transform Infra Red Spectroscopy (FTIR) 
Compatibility study of drug with the polymer was determined by FTIR Spectroscopy using 
Perkin Elmer RX1. The pellets were prepared by gently mixing of1mg sample with 200mg 
potassium bromide at high compaction pressure. The scanning range was 450 to 4000 cm -1and 
the revolution was 4 cm -1. The pellets thus prepared were examined and the spectra of drug and 
the polymer in the formulations were compared with that of pure drug or polymer spectra. 
Differential Scanning Calorimetry (DSC) 
Differential scanning calorimetric curve of pure rifampicin, poly lactic-co-glycolic acid (PLGA) 
polymer and mixture of drug and polymer measurement were carried out by using a thermal 
analysis instrument equipped with a liquid nitrogen sub ambient accessory. 2-6mg samples were 
accurately weighed in aluminum pans thematically sealed and heated at a rate of 10ºCper min -1 
in a 30 to 300 ºC temperature under nitrogen flow of 40 ml / min. 
7.2. Preparation of calibration curve for simultaneous estimation of rifampicin and 3FRSV 
by DW-Spectrophotometric method39 
 
Procedure for preparation of pH 1.2buffer 
 
50ml 0f 0.2M KCl is mixed with 85ml of 0.2M HCl and make upto 200ml with water. 
NOTE 
0.2M KCl: 14.911gm of KCl was dissolved in H2O and dilute with water and made upto 1000ml. 
0.2M HCl: 17ml of HCl was mixed with 1000ml 0f H2O. 
Preparation of standard stock solution 
 
RIF stock solution RIF powder (10mg) was accurately weighed and transferred to 10ml 
volumetric flask it was dissolved in 7ml of chloroform by sonication for 5min. The volume was 
adjusted to 10ml with chloroform. 1ml of this solution was further diluted to 10ml with 
chloroform to have the final concentration of 100mg/ml. 
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3-FRSV Stock solution 10mg was dissolved and diluted in chloroform as in case of RIF stock 
solution, to obtain the final concentration 100mg/ml.  
Selection of wavelength for the estimation of rifampicin 
 
Spectrum of pure 3-FRSV was scanned in the spectrum basic mode using the curser 
function, the absorbance corresponding to 475 nm was noted from the spectrum  then the curser 
function was moved along with peak curve until the absorbance was equal to that of absorbance 
at 475nm was found. The wavelength obtained corresponding to this absorbance value was 507 
nm. The absorbance of various dilution of 3-FRSV in chloroform was measured at 475 and 
507nm the difference between the two absorbance values was calculated. 
Selection of wave lengths for estimation of 3-FRSV 
 
Spectrum of pure RIF was scanned in the spectrum basic mode using the curser function; 
λ1 and λ2 were found as described above. The values obtained were 492nm (λ1) (the wavelength 
of maximum absorbance for 3FRSV) and 475nm (λ2), respectively. 
7.3. Calibration curve of rifampicin and 3-FRSV 
 
Appropriate aliquots from the stock solutions of RIF and 3FRSV were used to prepare 
four different sets of dilutions series A, B, C and D as follows. 
 
Series A:This series comprised of mixtures of RIF and 3FRSV having fixed concentrations of 
3FRSV (2µg/ml) and varying concentrations of RIF (5-50µg/ml). The solutions were prepared 
by pipetting out 0.2ml of 3FRSV stock solution (100µg/ml) and 0.5, 1.0, 1.5, 2, 2.5, 3.0, 3.5, 4.0, 
4.5 and 5ml of the stock solution of RIF (100µg/ml) in to a series of 10ml volumetric flask and 
the volume was adjusted to the mark with chloroform. 
 
Series B: This series comprised of mixtures of RIF and 3FRSV having fixed concentrations of 
RIF (50µg/ml) and varying concentrations of 3FRSV (2-10µg/ml) were prepared by pipetting out 
5ml of RIF stock solution (100µg/ml)and 0.2, 0.4, 0.6,0.8 and 1ml of the stock solution of the 
3FRSV (100µg/ml) into 10ml volumetric flask and volume was adjusted to the mark with 
chloroform. 
 
Series C: This series consisted of different concentration of RIF ranging from 5 to 50µg/ml 
prepared by appropriate dilution of aliquots of RIF stock solution, with chloroform, same as in 
the case of series A. 
 
39 
 
Series D: This series included solutions having concentrations of 3FRSV ranging from 2 to 
10µg/ml prepared by diluting appropriate volumes of corresponding stock solution with 
chloroform as in the case of series B. 
The absorbance of the solutions of series A and C were measured at 475.0(λ1) and 507nm (λ2) 
while absorbance of the solutions of seriesB and D where measured at 492(λ1) and 457nm(λ2). 
The difference in absorbance was plotted against concentration (µg/ml). 
In-vitro dissolution stability study of rifampicin alone at pH 1.2 buffer 
A solution of 0.1NHCL (200ml) was placed in the vessel of the USP dissolution 
apparatus 2 (us pharmacopoeia XXIII, 1995) and the medium was equilibrated at 37±0.2˚C with 
stirring at 100rpm. RIF (150mg) was accurately weighed, dissolved in and diluted to 100ml with 
0.1NHCL (37˚C). The resulting solution was transferred immediately to the dissolution vessel at 
once and 5ml of specimen was withdrawn immediately from a zone midway between the surface 
of the dissolution medium and bottom of the vessel(0min sample). Spacimens were withdrawn at 
15min intervals upto 60min. An aliquot, 1ml was extracted immediately with 5ml of chloroform 
using cyclomixer (3min). The aqueous phase was discarded and anhydrous sodium sulphate was 
added to chloroform layer to remove traces of water. The sample was analyzed for RIF and 
3FRSV using DW-Spectrophotometric method.39 
7.4. In-vitro dissolution stability study of rifampicin in the presence of fdc at pH 1.2 buffer 
 
Solution of 200ml 0.1N HCl was placed in the vessel of the dissolution apparatus and the 
medium was equilibrated to 37±0.2°C with stirring at 100 rpm. RIF (150mg) and INH (100mg) 
were accurately weighed, dissolved in and diluted to 100ml with 0.1N HCl (37°C), resulting 
solution was transferred immediately to the dissolution vessel and 5ml of specimen was 
withdrawn  immediately from a zone midway between the surface of the dissolution medium and 
bottom of the vessel(0min sample). Spacimens were withdrawn at 15min intervals upto 60min 
and analyzed as follows. 
Estimation of RIF and 3FRSV by DW-Spectrophotometric method 
 
An aliquot, 1ml was extracted immediately with 5ml of chloroform using cyclomixer 
(3min). The aqueous phase was discarded and anhydrous sodium sulphate was added to 
chloroform layer to remove traces of water. The samples was analyzed for RIF and 3FRSV using 
DW-Spectrophotometric method. 
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7.5. In-vitro dissolution stability study of rifampicin with different concentration of plga in 
the presence of fdc at pH 1.2 buffer 
 
Solution of 200ml 0.1N HCl was placed in the vessel of the dissolution apparatus and the 
medium was equilibrated to 37±0.2°C with stirring at 100 rpm. RIF (46.5mg), INH (24mg) 
PYZ(135.5mg),ETH(93mg)and plga(46.5mg) at varying strengths (1:1,1:2,1:3,1:1+fdc,1:2+fdc 
and 1:3+fdc) were accurately weighed, dissolved in and diluted to 100ml with 0.1N HCl (37°C), 
resulting solution was transferred immediately to the dissolution vessel and analyzed as 
described in 6.1.3. 
7.6. Statistics 
 
The values are expressed in mean ± S.D. One way ANOVA followed by Tukey’s 
multiple comparison Test was used to analyze the effect of different doses of silymarin when 
compared to control, with the help of Graph PadInstat software, version 3.01. P<0.05 was 
considered as significant.    
7.7. Preparation of rifampicin loaded plga nanoparticles 
            Rifampicin loaded plga nanoparticles were prepared through single emulsion evaporation 
method. 160mg of PLGA and 40mg of were dissolved in 2ml of dichloromethane. This solution 
was added drop wise to an aqueous 20ml PVA (3%, w/v) solution under sonication for 20 min 
(in pulsed manner, 40% intensity) using a probe sonicator (Lapsonic® P, Sartorious Biotech 
GmbH, Germany) over an ice bath. The solvent was evaporated at room temperature (28˚C) for 
12h, under magnetic stirring.  Loaded nanoparticles were isolated by 30 min centrifugation at 
35,000 rpm. After centrifugation, the supernatant was recovered and assayed for unentrapped 
drug and sediment was washed using the same amount of distilled water as of the supernatant 
and again centrifuged at 35,000 rpm for 20 min. The washing process was repeated 3 times. All 
the washings were collected and assayed for unentrapped drug. 
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Rifampicin Plga Loaded Nanoparticles 
 
Table:1 
Formulation   
code 
Drug Polymer Drug  polymer 
ratio 
Sonication 
time 
F1 31mg/kg 31mg/kg 1:1 20mins 
F2 31mg/kg 62mg/kg 1:2 20mins 
F3 31mg/kg 93mg/kg 1:3 20mins 
F4 31mg/kg 31mg/kg 1:1 along with 
FDC 
20 mins 
F5 31mg/kg 62mg/kg 1:2 along with 
FDC 
20 mins 
F6 31mg/kg 93mg/kg 1:3 along with 
FDC 
20 mins 
 
7.8. EVALUATION OF NANOPARTICLES 
7.8.1. Drug and carrier interaction by Fourier Transform Infra Red Spectroscopy 
Compatibility study of drug with the polymer was determined by FTIR Spectroscopy using 
Perkin Elmer RX1. The pellets were prepared by gently mixing of 1mg sample with 200mg 
potassium bromide at high compaction pressure. The scanning range was 450 to 4000 cm-1 and 
the revolution was 4 cm-1.  
7.8.2. Particle size determination by Scanning Electron Microscopy 62 
       The size of the nanoparticles was analyzed by scanning electron microscope .The instrument 
used for this determination was JEOL MODEL JSM 6400 scanning electron microscope (SEM). 
The nanoparticles were mounted directly on the SEM stub, using double –sided, sticking tape 
and coated with platinum and scanned in a high vacuum chamber with a focused electron beam. 
Secondary electrons, emitted from the samples were detected and the image formed. 
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7.8.3. Surface Characteristics by Zeta Potential 
             The Zeta potential of nanoparticles was measured on a zeta potential analyzer Zetasizer 
3000 HS Malvern instrument. The samples were diluted with pH 1.2 and placed in eletrophoretic 
cell and measured in the automatic mode. 
7.8.4. Thermal Analysis by Differential Scanning Calorimetry (DSC) 
Differential scanning calorimetric measurement of rifampicin  plga nanoparticles  was 
carried out by using a thermal analysis instrument equipped with a liquid nitrogen sub ambient 
accessory. 2-6mg samples were accurately weighed in aluminum pans thermatically sealed and 
heated at a rate of 10ºC per min -1 in a 30 to 300ºC temperature under nitrogen flow of 40 ml per 
min. 
7.8.5. Encapsulation efficiency and Percentage yield of the nanoparticles63 
The Encapsulation efficiency and percentage yield of the nanoparticles were determined 
by the separation of nanoparticles from the aqueous medium containing nonassociated rifampicin 
by cold centrifugation at 12000g for 30 minutes. The amount of free rifampicin in the 
supernatant was measured by UV method at 475nm. The rifampicin encapsulation efficiency 
(EE) and percentage yield of the nanoparticles was calculated as follows. 
                                             Total amount of Rifampicin– Free Rifampicin 
Encapsulation Efficiency = -------------------------------------------------------- x 100 
                                                              Weight of nanoparticles 
                                    Total amount of Rifampicin – Free Rifampicin 
Percentage yield =  --------------------------------------------------------- × 100 
                                                Total amount of Rifampicin 
7.8.6. Invitro release of rifampicin from the nanoparticles 
Dissolution studies 
The dissolution profiles of the plain drug and the nanoparticle formulations were 
determined in USP dissolution apparatus – II using 900ml of pH – 1.2 buffer for the 60 mins . 
The dissolution media were maintained at 37°±0.5°C with a paddle rotation speed at 50 rpm. The 
amount of drug used was equivalent to 2 mg. At specified time intervals (15, 30, 45 and 60 mins) 
5ml of dissolution media were withdrawn and replaced with an equal volume of the fresh 
medium to maintain constant volume of the media. Samples were filtered through a0.22µm nylon 
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membrane filter (Millipore, Bedford, MA) and assayed for drug content spectrophotometrically 
at 475nm using UV/Vis double beam spectrophotometer after appropriate dilution with the 
corresponding media. Cumulative percentage of drug dissolved in the preparations was 
calculated using calibration equations. Dissolution tests were performed in triplicate for each 
formulation (n = 3).64 
Diffusion studies 
The rifampicin loaded plga nanoparticles were separated from the aqueous suspension 
medium through ultracentrifugation. Nanoparticles equivalent to 2mg of rifampicin nanoparticles 
were redispersed in 10ml phosphate buffer solution pH-1.2and placed in a dialysis membrane 
bag with a molecular cut-off of 5 kDa which acts as a donor compartment, tied and placed into 
10 ml 1.2 phosphate buffer solution in a beaker which acts as a receptor compartment .The entire 
system was kept at 37ºC with continuous magnetic stirring. At appropriate time intervals (15, 30, 
45 and 60 mins) 1 ml of the release medium was removed and 1 ml fresh 1.2phosphate buffer 
solution was added in to the system. The amount of rifampicin in the release medium was 
evaluated by UV-Visible Spectrophotometer at 475 nm. 
7.8.7. Kinetics of drug release65, 66 
In order to understand the mechanism and kinetic of drug release, the drug release data of 
the in-vitro dissolution study were analyzed with various kinetic models like zero order, first 
order, Higuchi’s, Peppa’s and Coefficient of correlation (r) values were calculated for the linear 
curves by regression analysis of the above plots. 
I) Fitting of Results into Different Kinetic Equations 
The results of in vitro release profile obtained for all the formulations were plotted in 
modes of data treatment as follows: -  
a. Zero - order kinetic model - Cumulative % drug released versus time. 
b. First – order kinetic model - Log cumulative percent drug remaining versus time. 
c. Higuchi’s model - Cumulative percent drug released versus square root of time. 
d. Korsmeyer equation / Peppa’s model - Log cumulative percent drug released versus log time. 
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A) Zero order kinetics  
Zero order release would be predicted by the following equation 
At = A0 – K0t    
Where,  
At   = Drug release at time‘t’. 
A0  = Initial drug concentration. 
K0  = Zero - order rate constant (hr-1). 
When the data plotted as cumulative percent drug release versus time, and the plot is linear, and 
then the data obeys Zero – order equal to K0. 
B) First Order Kinetics 
First – order release would be predicted by the following equation:- 
Log C = log C0 – Kt / 2.303 
Where,      C   = Amount of drug remained at time‘t’. 
      C0 = Initial amount of drug. 
      K   = First – order rate constant (hr-1). 
When the data plotted as log cumulative percent drug remaining versus time yields a 
straight line, then the release follow first order kinetics. The constant ‘K’ can be obtained by 
multiplying 2.303 with the slope values.  
C) Higuchi’s model: Drug release from the matrix devices by diffusion has been described by 
following Higuchi’s classical diffusion equation 
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Q = [Dε / τ (2 A - εCs) Cst] ½ 
 
Where, 
Q = Amount of drug released at time‘t’. 
D = Diffusion coefficient of the drug in the matrix. 
A = Total amount of drug in unit volume of matrix. 
Cs = the solubility of the drug in the matrix. 
ε = Porosity of the matrix. 
τ = Tortuosity. 
t = Time (hrs) at which ‘q’ amount of drug is released. 
Above equation may be simplified if one assumes that ‘D’, ‘Cs’ and ‘A’ are constant. 
Then equation becomes            
Q = Kt1/2 
When the data plotted according to equation i.e. cumulative drug release versus square 
root of time yields a straight line, indicating that the drug was released by diffusion mechanism. 
The slope is equal to ‘K’ (Higuchi’s 1963). 
D) Korsmeyer equation / Peppa’s model  
To study the mechanism of drug release from the sustained-release of acyclovir 
nanoparticles, the release data were also fitted to the well-known exponential equation 
(Korsmeyer equation/ peppa’s law equation), which is often used to describe the drug release 
behavior from polymeric systems. 
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Mt / Mα = Ktn 
Where, Mt / Mα = the fraction of drug released at time‘t’.  
             K = Constant incorporating the structural and geometrical characteristics of the drug / 
polymer system. 
              n = Diffusion exponent related to the mechanism of the release. 
Above equation can be simplified by applying log on both sides, 
And we get: - Log Mt / Mα = Log K + n Log t 
When the data plotted as log of drug released versus log time, yields a straight line with a slope 
equal to ‘n’ and the ‘K’ can be obtained from y – intercept. For Fickian release ‘n’ = 0.5 while 
for anomalous (non - Fickian) transport ‘n’ ranges between 0.5 and 1.0. 
Mechanism of Drug Release as per Korsmeyer Equation / Peppa’s Model 
S. No. n Value Drug release 
1.  0.50 Fickian release 
2.  0.5 < n <1.0  Non – Fickian release 
3.  1.0 Case II transport 
E). Statistical analysis: The release data were subjected to ANOVA with Tukey-Kramer 
multiple comparision test. 
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7.9. IN-VIVO EVALUATION STUDIES 
7.9.1 Animals: New Zealand white rabbits weighing 1.5 to 2.5kg were obtained from Swamy 
Vivekananda College of pharmacy animal house was used in this study. The animals were fed 
with cabbage and water. They were maintained in standard laboratory conditions 21±2 0C and 
relative humidity of 55-60%. The animals are overnight fasted before the experiment. The study 
protocol was approved by the Institutional Animal Ethical Committee and the protocol number is 
SVCP/IAEC/M.Pharm/07/2013. 
Requirements  
Cotton 
   Surgical blade 
   26G needle 
   Blood collecting tubes (EDTA tubes)  
   Plasma sample collecting tubes 
Sex   Male 
No. of animals 6 
 
7.9.2 Animal dose  
Rifampicin        : 31mg/kg 
Rifampicin nanoparticles: 31 mg/kg 
           Rifampicin nanoparticles   +     isoniazid   +    prrazinamide    +    etambutal 
               31mg/kg                           +      16mg/kg   +    77mg/kg             +     62mg/kg 
7.9.3 Procedure for collection of blood 
 
Collection of blood from marginal ear vein 
 
 The animal was placed in a restrainer. Hair of the ear was shaved smoothly with blade 
without disturbing the blood vessels. Ear was cleaned with 95% v/v alcohol on the collection site 
and rapid rubbing on the ear to  dilate blood vessels which is easy to collect the blood. 2G needle 
was inserted in vein to collect the blood from marginal ear vein. After collecting blood, clean 
sterile cotton was kept on the collection site and finger pressure was applied to stop the 
bleeding.71 
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7.9.4 Experimental procedure: Rabbits were classified into 4 different groups each group 
consisting of 6 animals 
 
GROUP I Rifampicin 
GROUP II Rifampicin+ fdc 
GROUP III Rifampicin+ plga nanoparticles 
GROUP IV     Rifampicin+plga nanoparticles+fdc 
Procedure :After overnight fasting, Group1, Group 2, Group3,Group 4 animals received 
rifampic alone (31mg/kg), rifampicin (31mg/kg)+ isoniazid(16mg/kg)+pyrazinamide(77mg/kg)+ 
ethambutol(62mg/kg),rifampicin(31mg/kg)+PLGA(93mg/kg)and,rifampicin(31mg/kg)+PLGA(9
3mg/kg))+ isoniazid(16mg/kg) + pyrazinamide(77mg/kg) + ethambutol(62mg/kg)  respectively 
through an intragastric tube. Blood samples (1 ml) were collected in heparinized tubes from the 
marginal ear vein at 0, 0.5, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12 and 24 h after drug administration 
and plasma was separated by using centrifugation and stored at -20°C. Samples were analyzed 
by validated high performance liquid chromatography (HPLC).4 
7.9.5 Bioanalytical work 
Extraction of RIF, 3FRSV from plasma 
 
An aliquot of 500µl of plasma samples was pipetted into an eppendrof’s tube of 1.5ml capacity. 
500µl methanol was added, vortexed for 3 minute and centrifuged at 10,000 rpm for 15min. 
Then 300 µl of the supernatant was taken into another microcentrifuge tube and vaccum dried in 
centrivac. The residue obtained was reconstituted in 100µl of mobile phase. Plasma was filtered 
through 0.22 µm membranes (13 mm) and 20 µl volumes were injected. All the two analytes; 
RIF, 3FRSV were detected at 238nm73 
7.9.5.1 Chromatographic conditions73 
The parameters specified by USP for gradient HPLC analysis of RIF, 3FRSV are given in 
Table 1. The prescribed gradient program for analysis is given in Table 2. The analysis was done 
maintaining all the specified conditions 
 
 
 
 
 
49 
 
Table: 2 HPLC parameters for determination of R, H and Z by the proposed USP method 
 
Parameter Condition 
Column L1 (250×4.6 mm) 
 
Particle size 5µm 
Mobile phase Buffer solution:1.4g of dibasic sodium 
Phosphate in 1 liter water (pH 6.8) 
Solution A=Buffer:ACN(96:4) 
Solution B=Buffer:ACN(45:55) 
Flow rate 1.5ml\min 
Detection wavelength 238nm 
Column temperature 25 c 
Injection volume 20µl 
 
 
Table: 3 Gradient programs prescribed in the USP method 
 
Time (min) Solution A(%) Solution B(%) Elution 
0 100 0 Equilibration 
0-5 100 0 Isocratic 
5-6 100-0 0-100 Linear gradient 
6-15 0 100 Isocratic 
 
Extraction efficiency 
 
 The extraction efficiency was calculated by comparing the peak heights of rifampicin 
spiked-pooled blank plasma samples with that of respective standard rifampicin samples 
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7.9.6.  Pharmacokinetic parameters74 
The pharmacokinetic parameters were calculated for each rabbit of group I, group II, group III 
and group IV, by the semi logarithmic plot of plasma rifampicin concentration at various 
intervals. The following pharmacokinetic parameters were calculated: 
 
a. Elimination rate constant(Ke): The elimination rate constant was determined using the formula 
1. Ke = -2.303 x slope of extrapolated curve 
b. Elimination half life(t1/2):t1/2 was calculated using the formula 
t1/2= 0.693/Ke 
 
1. Absorption rate constant (Ka): This was determined by the method of residuals. The log linear 
portion of the decline phase was back extrapolated for each curve. The plasma concentration 
along this extrapolated line was C. the observed plasma concentration C was subtracted from 
the corresponding extrapolated value at each time point. The semi logarithmic plot of residuals 
(C-C) against time yields a straight line. 
 
Ka= -2.303 x slope of residual line 
 
2. Absorption half life: It was calculated using the formula 
 
T1/2(a) = 0.693/Ka 
 
3. Apparent volume of distribution(Vd):It was calculated using the formula 
 
1. Vd=            Ka F X0 
(Ka - Ke) y intercept 
4. Time to Cmax(tmax):tmax was calculated using the formula 
 
tmax=        lnKa - lnKe 
Ka-Ke 
 
5. Maximum plasma concentration (Cmax): Cmax was calculated using the formula 
 
Cmax =    Y intercept (e
-Ke. Tmax
 – e
-Ka.Tmax
) 
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6. Area under curve (AUC0-12): AUC0-12 was calculated using the formula 
 
 
AUC   =        F X0 
Vd.Ke 
 
7. AUC0-∞ was calculated using the formula 
 
AUC0-∞  =    C0 
Ke 
Statistics 
 
The values are expressed in mean ± SEM. One way ANOVA followed by Tukey’s multiple 
comparison Test was used to analyse the effect of different doses of silymarin when compared to 
control, with the help of Graph PadInstat software, version 3.01. P<0.05 was considered as 
significant.                 
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8. RESULTS 
 
 
COMPATIBILITY STUDIES: 
8.1.  Drug and carrier intereaction by FT-IR Spectroscopy 
FT-IR spectra of rifampicin, PLGA in physical mixture of rifampicin and plga and 
rifampicin loaded plga nanoparticles are shown in tables8, 9, 10 and 11 and figures 4, 5, 6 and 7. 
Rifampicin showed from characterstic peaks at 2885.6 cm-1 (C-H-alkyl strecting), 1699.34 cm-
1(C=O-aromatic ketones), 1651.34cm-1(COOH unsaturated carboxylic acid stretching), 
3043.77cm-1(O-H carboxylic acid-stretching). All these characteristic peaks present in  
rifampicin physical mixed observed in nanoparticles and thus conforming drug and polymer 
were compatable.  
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Sl.no 
 
 
IRSpectrum 
 
 
Peaks(cm-1) 
 
 
Groups 
 
Stretching 
/Deformation 
 
 
 
 
1 
 
 
 
 
Rifampicin 
 
2885.6 
 
C-H(alkyl) 
 
Stretching 
1699.34 C=O(aromaticketone) Stretching 
 
1651.12 
COOH(unsaturated 
carboxylicacid) 
 
Stretching 
3043.77 O-H(Carboxylicacid) Stretching 
 
                                      IR SPECTRUM OF RIFAMPICIN 
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                                          Fig :1  IR SPECTRUM OF RIFAMPICIN 
 
 
 
 
 
 
2 
 
 
Blank 
nanoparticles of 
plga 
2872.1 C-H(alkyl) Stretching 
1653.05 C=O(aromaticketone) Stretching 
 
1629.6 
COOH(unsaturated 
carboxylicacid) 
 
Stretching 
3084.28 O-H(Carboxylicacid) Stretching 
      
            IR SPECTRUM OF BLANK NANOPARTICLES USING PLGA 
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                     Fig: 2 IR SPECTRUMS OF BLANK NANOPARTICLES USING PLGA 
 
 
 
 
3 
 
Physical mixture 
of Rifampicin and 
plga 
2891.39 C-H(alkyl) Stretching 
1697.41 C=O(aromaticketone) Stretching 
 
1651.12 
COOH(unsaturated 
carboxylicacid) 
 
Stretching 
3045.7 O-H(Carboxylicacid) Stretching 
             
  IR SPECTRUM OF PHYSICAL MIXTURE OF RIFAMPICIN WITH PLGA 
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         Fig:3   IR SPECTRUM OF PHYSICAL MIXTURE OF RIFAMPICIN WITH PLGA 
 
 
 
 
 
4 
 
 
Rifampicin 
nanoparticles of 
Plga 
2856.67 C-H(alkyl) Stretching 
1654.98 C=O(aromaticketone) Stretching 
 
1645.03 
COOH(unsaturated 
carboxylicacid) 
 
Stretching 
2926.11 O-H(Carboxylicacid) Stretching 
 
IR SPECTRUM OF RIFAMPICIN NANOPARTICLES 
 
Fig:4  IR SPECTRUM OF RIFAMPICIN NANOPARTICLES 
 
 
     
57 
 
8.2. B. Differential scanning calorimetry (DSC) 
In order  to   confirm the physical state of rifampicin in the nanoparticles , DSC of the 
RIF ,physical mixture of RIF and polymer, RIF nanoparticles and blank nanoparticles,was 
carried out and the results are shown in figures 8,9,10,11,12 and 13. The DSC thermogram of 
RIF showed a sharp endothermic peak at 94.96°C, its melting point.The physical mixture of RIF 
and polymer,showed the same thermal behavior 93.04°C as the individual component, 
indicating that there was no interaction between the RIF and the polymer in the solid state. The 
DSC thermogram of blank nanoparticles showed a single endothermic peak at 80.72°C, the 
melting point of PLGA. The nanoparticles of F1,F2 ,F3,F5and F6, showed endothermic 
peak at 68.75°C, 81.59°C and 92.05°C respectively,which are the characterstic peaks of  
PLGA shifted from 80.72°C , and there was no evidence for presence of the character 
peaks of  RIF at 94.96°C in F1,F2,F3,F4,F5 and F6. The change in thermogram indicate that 
RIF existed in an amorphrous form completely where as the PLGA partially changes to 
amorphous state.  
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                                     Fig:5   DSC thermogram of rifampicin 
     
 
 
                               Fig:6  DSC thermogram of blank nanoparticles using Plga 
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                      Fig:7   DSC thermogramof  physical mixture of Rifampicin and plga 
 
                            Fig:8  DSCthermogram of Rifampicin nanoparticles using plga 
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                              Fig:9  DSC thermogram of Rifampicin nanoparticles using plga 
 
 
                                  
Fig:10  DSC thermogram of Rifampicin nanoparticles using plga 
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8.3. Encapsulation efficiency and percentage yield: 
The entrapment efficiency of F1,F2 ,F3,F4,F5and F6 were 58.54%, 68.44% ,71.32 
73.12%,75.41and 76.11 respectively. Similarly the percentage yield increses in the 
concentration of plga increases. The percentage yield of F1, F2, F3, F4, F5 and F6 were 50.91, 
60.46, 67.31, 83.86, 85.22and 87.44respectively. Table 12 shows the results of encapsulation 
efficiency and percentage yield of the rifampicin nanoparticles. 
 
Formulation 
Code 
Drug polymer 
ratio (mg) 
Encapsulation 
Efficiency (%) 
Percentage yield 
(%) 
F1 1:1 58.54 50.91 
F2 1:2 68.44 66.46 
F3 1:3 71.32 67.31 
F4 1:1along with FDC 73.12 83.36 
F5 1:2 along with 
FDC 
75.41 85.22 
F6 1:3 along with 
FDC 
76.11 87.44 
 
Table:8 encapsulation efficiency and percentage yield of the nanoparticles 
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8.4. Morphology: 
           The SEM of nanoparticles are shown in figures, The particles was formed smooth and 
spherical in shape at the drug:polymer ratio 1:1 in F1 and remained  in the same characterstic  at 
higher concentration of the polymer as seen in F2,F3,F4,F5 and F6 formulations.  
SEM IMAGES: 
    Fig:11  (F) 
 
        
 
 
 
 
 
 
 
63 
 
Fig:12  (F0) 
 
 
 
Fig:13   (F3) 
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8.5. PARTICAL SIZE: 
The mean particle size of F1, F2,F3,F4,F5 and F6 formulations ,obtained by zetasizer analysis 
were  298,495,596,  698 859,892nm (table 13) respectively. The particle size of nanoparticles 
was found increases with increase in the polymer concentration. 
 Table:9 Particle size, Zeta potential and PDI of Rifampicin loaded  nanoparticles 
Formulation 
code 
Drug  
polymer 
ratio (mg) 
Particle size Zeta 
potential(mv) 
PDI 
F1 1:1 298±0.25nm -0.27±1.2mV 0.195±0.35 
F2 1:2 495±0.12nm -0.22±2.8mV 0.238±0.39 
F3 1:3 596±0.52nm -0.20±2.8mV 0.325±0.51 
F4 1:1 (along 
with Fdc) 
698±0.52nm -0.18±1.8mV 0.325±0.35 
F5 1:2(along 
with Fdc) 
859±0.25nm -0.16±1.4 mV 0.435±0.39 
F6 1:3(along 
with Fdc) 
892±0.12nm -0.14±1.2 mV 0.541±0.35 
  
8.6.  Zeta potential: 
         The zeta performed of F1, F2, F3, F4, F5 and F6 formulations are shown in table 13. The 
zeta potential of nanoparticles ranges from -0.14 to -0.27 the least zeta potential with F6 and the 
ahighest value with F1. The zeta potential decreases with increase in the concentration of the 
polymer. 
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 8.7. Polymer dispersive index: 
  The PDI of F1, F2, F3, F4, F5 and F6 are shown in table. The PDI of all these formulations 
easily formed to be less than 0.5 indicating homogenous dispersion of the drug. The results are 
showed in table 13. 
  
 
 
                                                Fig:14   Rifampicin zeta 
 
 
8.8. In vitro release of rifampicin nanoparticles 
The diffusion profile of F1,F2, F3,F4,F5and F6  are presented in tables.  The present drug 
diffused at every time point interval significantly dispersed between F1,F2 F3,F4,F5,F6. The 
diffusion  rate with F5 and F6 was slower compared  to F1.     
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Table :10  In Vitro Release Data For Pure Rifampicin(F): 
Time Trail 1 Trail 2 Trail 3 Cumulative % 
drug release 
 
0 
 
0 
 
0 
 
0 
 
0 
 
15 
 
30 
 
32.5 
 
35.1 
 
32.4 ± 2.554 
 
30 
 
41 
 
42.5 
 
40.1 
 
41.2 ± 1.212 
 
45 
 
 
48 
 
47.6 
 
45.1 
 
46.9 ± 1.572 
 
60 
 
56 
 
56.4 
 
59.4 
 
57.2 ± 1.858 
 
 
              
   
                          Fig:15   Percentage Drug release 
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Table :11 Kinetic release data for pure rifampicin (F) 
Time in 
mints 
Square 
root of 
time 
Log time Cumulative 
% drug 
release 
Log 
cumulative 
% drug 
release 
Cumulative 
% drug 
remaining 
Log 
cumulative 
% drug 
remaining 
0 0 0 0 0 100 2 
15 3.872 1.176 32.4 1.510 67.6 1.829 
30 5.477 1.477 41.2 1.614 58.8 1.769 
45 6.708 1.653 46.9 1.671 53.1 1.725 
60 7.745 1.778 57.2 1.757 42.8 1.631 
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Fig: 15(a) 
                                
Fig:15(b) 
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Fig:15(c) 
 
 
 
 
Fig:15(d) 
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Table: 12 In vitro release data for rifampicin in rifampicin along with FDC(F0): 
Time Trail 1 Trail 2 Trail 3 Cumulative % 
drug release 
 
0 
 
0 
 
0 
 
0 
 
0 
 
15 
 
14 
 
13.9 
 
14.3 
 
14 ± 0.2082 
 
30 
 
18 
 
18.5 
 
19 
 
18.5 ± 0.5 
 
45 
 
 
21 
 
22 
 
20.5 
 
21.1 ± 0.7638 
 
60 
 
26 
 
25.3 
 
26.7 
 
26 ± 0.7 
 
 
 
 
                            Fig:16              Percentage Drug release 
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Table: 13 Kinetic release data for pure rifampicin (F0) 
Time in 
mints 
Square 
root of 
time 
Log time Cumulative 
% drug 
release 
Log 
cumulative 
% drug 
release 
Cumulative 
% drug 
remaining 
Log 
cumulative 
% drug 
remaining 
0 0 0 0 0 100 2 
15 3.872 1.176 14 1.146 86 1.934 
30 5.477 1.477 18.5 1.267 81.5 1.911 
45 6.708 1.653 21.1 1.324 78.9 1.897 
60 7.745 1.778 26 1.414 74 1.869 
 
 
 
                                            Fig:16(a) 
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                                               Fig:16(b) 
 
 
 
 
                                                  Fig:16(c) 
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Fig:16(d) 
Table :14  In vitro release data for rifampicin in rifampicin + PLGA 1:1 (F1): 
Time Trail 1 Trail 2 Trail 3 Cumulative % 
drug release 
 
0 
 
0 
 
0 
 
0 
 
0 
 
15 
 
15 
 
14.9 
 
15.3 
 
15 ± 0.2082 
 
30 
 
24 
 
24.6 
 
23.9 
 
24.1 ± 0.3786 
 
45 
 
26 
 
26.2 
 
25 
 
26.4 ± 0.5292 
 
60 
 
35 
 
34.8 
 
35.2 
 
35 ± 1.332 
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                                                 Fig: 17 Percentage Drug release   
Table :15  Kinetic release data for rifampicin in rifampicin + PLGA 1:1 (F1) 
Time in 
mints 
Square 
root of 
time 
Log time Cumulative 
% drug 
release 
Log 
cumulative 
% drug 
release 
Cumulative 
% drug 
remaining 
Log 
cumulative 
% drug 
remaining 
0 0 0 0 0 100 2 
15 
3.872 1.176 15 1.176 85 1.929 
30 
5.477 1.477 24.1 1.382 75.9 1.880 
45 
6.708 1.653 26.4 1.421 73.6 1.866 
60 
7.745 1.778 35 1.544 65 1.812 
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 Fig:17(d) 
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Table :16 In vitro release data for rifampicin in rifampicin + PLGA 1:2 (F2): 
Time Trail 1 Trail 2 Trail 3 Cumulative % 
drug release 
 
0 
 
0 
 
0 
 
0 
 
0 
 
15 
13 13.3 12.7 13 ± 0.3 
 
30 
15 16.2 15.3 15.5 ± 0.625 
 
45 
19 20 19.4 19.8 ± 0.721 
 
60 
31 31.3 32 31.4 ± 0.513 
 
 
 
 
 
           Fig:22 Percentage Drug release 
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Table :18  Kinetic release data for rifampicin in rifampicin + PLGA 1:2 (F2) 
Time in 
mints 
Square 
root of 
time 
Log time Cumulative 
% drug 
release 
Log 
cumulative 
% drug 
release 
Cumulative 
% drug 
remaining 
Log 
cumulative 
% drug 
remaining 
0 0 0 0 0 100 2 
15 3.872 1.176 13 1.113 87 1.939 
30 5.477 1.477 15.5 1.190 84.5 1.926 
45 6.708 1.653 19.8 1.296 80.2 1.904 
60 7.745 1.778 31.4 1.496 68.6 1.836 
 
 
 
   Fig:18(a) 
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Table :18  In vitro release data for rifampicin in rifampicin + PLGA 1:3 (F3): 
Time Trail 1 Trail 2 Trail 3 Cumulative % 
drug release 
 
0 
 
0 
 
0 
 
0 
 
0 
 
15 
 
10 
 
10.3 
 
9.7 
 
10 ± 0.3 
 
30 
 
13.4 
 
13.2 
 
14 
 
13.4 ± 0.5292 
 
45 
 
18 
 
18.7 
 
17.8 
 
18 ± 0.4726 
 
60 
 
28 
 
28.3 
 
29.2 
 
28 ± 0.4726 
 
 
 
 
                           Fig:19  Percentage Drug release 
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Table :19  Kinetic release data for rifampicin in rifampicin + PLGA 1:3 (F3) 
Time in 
mints 
Square 
root of 
time 
Log time Cumulative 
% drug 
release 
Log 
cumulative 
% drug 
release 
Cumulative 
% drug 
remaining 
Log 
cumulative 
% drug 
remaining 
0 0 0 0 0 100 2 
15 3.872 1.176 10 1 90 1.954 
30 5.477 1.477 13.4 1.127 86.6 1.937 
45 6.708 1.653 18 1.255 82 1.913 
60 7.745 1.778 28 1.447 72 1.857 
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Table :20  In vitro release data for rifampicin in rifampicin + PLGA 1:1 along with FDC 
(F4): 
Time Trail 1 Trail 2 Trail 3 Cumulative % 
drug release 
 
0 
 
0 
 
0 
 
0 
 
0 
 
15 
 
8 
 
8.7 
 
9.5 
 
8.5 ± 0.513 
 
30 
 
11 
 
11.3 
 
12 
 
11.4 ± 0.513 
 
45 
 
17 
 
15.1 
 
16.7 
 
16.9 ± 0.208 
 
60 
 
22.4 
 
22.3 
 
23 
 
22.4 ± 0.513 
 
 
 
 
                           Fig: 20 Percentage Drug release 
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Table: 21 Kinetic release data for rifampicin in rifampicin + PLGA 1:1 along with FDC 
(F4) 
Time in 
mints 
Square 
root of 
time 
Log time Cumulative 
% drug 
release 
Log 
cumulative 
% drug 
release 
Cumulative 
% drug 
remaining 
Log 
cumulative 
% drug 
remaining 
0 0 0 0 0 100 2 
15 3.872 1.176 8.5 0.929 91.5 1.961 
30 5.477 1.477 11.4 1.056 88.6 1.947 
45 6.708 1.653 16.9 1.227 83.1 1.919 
60 7.745 1.778 22.4 1.350 77.6 1.889 
             
                                                    
                                                                               Fig: 20(a) 
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                                                  Fig: 20(b) 
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Table: 22 In vitro release data for rifampicin in rifampicin + PLGA 1:2 along with FDC 
(F5): 
Time Trail 1 Trail 2 Trail 3 Cumulative % 
drug release 
 
0 
 
0 
 
0 
 
0 
 
0 
 
15 
 
6.5 
 
6.3 
 
5.7 
 
6.5 ± 0.513 
 
30 
 
9.9 
 
9.7 
 
8.8 
 
9.4 ± 0.513 
 
45 
 
13 
 
14.1 
 
15 
 
14.9 ± 0.208 
 
60 
 
19.4 
 
20 
 
21.3 
 
20.4 ± 0.513 
 
 
 
 
                       Fig: 21 Percentage Drug release 
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Table: 23 Kinetic release data for rifampicin in rifampicin + PLGA 1:2 along with FDC 
(F5) 
Time in 
mints 
Square 
root of 
time 
Log time Cumulative 
% drug 
release 
Log 
cumulative 
% drug 
release 
Cumulative 
% drug 
remaining 
Log 
cumulative 
% drug 
remaining 
0 0 0 0 0 100 2 
15 3.872 1.176 6.5 0.812 93.5 1.970 
30 5.477 1.477 9.4 0.973 90.6 1.957 
45 6.708 1.653 14.9 1.173 85.1 1.929 
60 7.745 1.778 20.4 1.309 79.6 1.900 
            
                            
                                                                          Fig: 21 (a) 
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                                                    Fig: 21 (b) 
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Table :24  In vitro release data for rifampicin in rifampicin + PLGA 1:3 along with FDC 
(F6): 
Time Trail 1 Trail 2 Trail 3 Cumulative % 
drug release 
 
0 
 
0 
 
0 
 
0 
 
0 
 
15 
 
4 
 
9 
 
5.7 
 
4.5 ± 0.513 
 
30 
 
10 
 
10.3 
 
9 
 
9.3 ± 0.513 
 
45 
 
13 
 
13.6 
 
14 
 
13.2 ± 0.208 
 
60 
 
17 
 
16.7 
 
17.8 
 
17.2 ± 0.513 
 
 
 
                 Fig: 22 Percentage Drug release 
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Table :25  Kinetic release data for rifampicin in rifampicin + PLGA 1:3 along with FDC 
(F6) 
Time in 
mints 
Square 
root of 
time 
Log time Cumulative 
% drug 
release 
Log 
cumulative 
% drug 
release 
Cumulative 
% drug 
remaining 
Log 
cumulative 
% drug 
remaining 
0 0 0 0 0 100 2 
15 3.872 1.176 4.5 0.653 95.5 1.980 
30 5.477 1.477 7.4 0.869 92.6 1.966 
45 6.708 1.653 11.9 1.075 88.1 1.944 
60 7.745 1.778 18.4 1.264 81.6 1.911 
 
 
                                                Fig: 22 (a) 
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                                                Fig:22 (b) 
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Table: 26 COMPARITIVE % DRUG RELEASE  
 
 
   Fig: 23 
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% (F)drug release
% (F0)drug release
% (F1)drug release
% (F2)drug release
% (F3)drug release
%(F4) drug release
%(F5)drug release
%(F6)drug release
Tim
e 
RIF 
ALONE 
RIF+FD
C 
RIF+PLGA 
1:1 
RIF+PLG
A 1:2 
RIF+PLGA 
1:3 
RIF+PLGA 
1:1+FDC 
RIF+PLG
A 
1:2+FDC 
RIF+PLG
A 
1:3+FDC 
0 0 0 0 0 0 0 0 0 
15 32.4±2.554 14±0.208 15±0.208 13±0.3 10±0.3 8.5±0.513 6.5±0.513 4.5±0.513 
30 41.2±1.212 18.5±0.5 24.1±0.378 15.5±0.624 13.4±0.529 11.4±0.513 9.4±0.513 9.3±0.513 
45 46.9±1.572 21.1±0.76
3 
26.4±0.529 19.8±0.721 18±0.472 16.9±0.208 14.9±0.208 13.2±0.108 
60 57.2±1.858 26±0.7 35±1.332 31.4±0.513 28±0.472 22.4±0.513 20.4±0.513 17.2±0.513 
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8.9. Table :27  In vitro release kinetic data Rifampicin loaded nanoparticles (DIFFUSION) 
Formulation 
code 
First 
order 
“R2”value 
Zero 
order 
“R2”value 
Higuchi 
plot 
“R2”value 
Peppas 
plot 
“R2”value 
n  
value 
 
F1 
 
0.959 
 
0.978 
 
0.957 
 
0.966 
 
0.580 
 
F2 
 
0.888 
 
0.986 
 
0.824 
 
0.837 
 
0575 
 
F3 
 
0.935 
 
0.989 
 
0.883 
 
0.908 
 
0.688 
 
F4 
 
0.982 
 
0.992 
 
0.948 
 
0.953 
 
0.706 
 
F5 
 
 
0.982 
 
0.994 
 
0.948 
 
0.965 
 
0.814 
 
F6 
 
0.970 
 
0.998 
 
0.929 
 
0.966 
 
0.992 
                       K0- Zero order rates constant 
  K1 – First order rate constant 
  R – Coefficient of correlation 
  N – Diffusion exponent 
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The regression co-efficient values are zero order plots were compared. It was observed 
that the “R” value of zero order plit were in the range of 0.976to 0.988 from all the six 
formulations. The “R” values of first order plot were in the range of 0.959 to 0.970 based on the 
highest regression values (R), the best fit model for F1, F2, F3, F4 and F6. Followed zero order 
release. The “R” value of the linear regression for korsmeyer plot were found in the range of 
0.966 to 0.966 for all the formulation indicating that the data fit into the korsmeyer plot model 
well, and the drug release was found to be predominantely controlled by swelling process. 
When the slope n values of formulation F1,F2, F3,F4,F5 and F6 in korsmeyer equation 
(F1=0.966, F2=0.837 F3=0.908,F4=0.953,F5=0-.965 and F6=0.966) were compared, it was 
observed that increasing polymer concentration in the nanoparticle led to increase in the slope 
value from 0.580 to 0.992 indicating that the drug release by Non –Fickian release. (n<1.0) Non 
–Fickian release mechanism which involves swelling controlled release of the drug. 
Turkey – Kramer multiple camparision test: t90 
The release data were subject to ANOVA with Turkey- Kramer comparision test F2 
showed release pattern as compared F1 (p<0.05) .Similar release behavior was observed between 
F3 and F1 (p<0.001) and between F4 and F1 (p<0.05).Simillarly the release behavior was 
observed between F5 and F1(P<0.05). Similar release behavior was observed between F6 And 
F1(p<0.001).F3 showed release pattern as compared F2 (p<0.05).Similar release behavior was 
observed between F3 and F2 (p<0.001) and between F4 and F2 (p<0.05) Simillarly the release 
behavior was observed between F5 and F2(P<0.05). Similar release behavior was observed 
between F6 And F2(p<0.001) .F4 showed release pattern as compared F3 (p<0.05).Similar 
release behavior was observed between F4 and F3 (p<0.001) and between F5 and F3 (p<0.05) 
.Similar release behavior was observed between F6 And F3(p<0.001) F5 showed release pattern 
as compared F4 (p<0.05).Similar release behavior was observed between F5 and F4 (p<0.05). 
Similar release behavior was observed between F6 And F4(p<0.001). Similar release behavior 
was observed between F5 And F6(p<0.001)The result suggest that the slow drug release 
characterstics appear to be influenced by polymer concentration 
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Table: 28 Turkey – Kramer multiple comparison test: t90 
Comparision “p” value 
F1 Vs F2 P< 0.05 
F1 Vs F3 P< 0.001 
F1 Vs F4 P< 0.05 
F1VsF5 P< 0.05 
F1VsF6 P< 0.001 
F2VsF3 P< 0.05 
F2VsF4 P< 0.05 
F2VsF5 P< 0.05 
F2VsF6 P< 0.001 
F3VsF4 P< 0.05 
F3VsF5 P< 0.05 
F3VsF6 P< 0.001 
F4VsF5 P< 0.05 
F4VsF6 P< 0.001 
F5VsF6 P< 0.001 
 The “P” value is <0.0001, considered extremely significant. Variation among column means 
is significantly greater than expected by chance.  
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Dissolution stability of rifampicin alone at pH 1.2 buffers 
The result of dissolution stability study of the RIF alone was shown in Tables 29,30 and 31 and  
and figures 24 and 25. The degradation of RIF was increased gradually over the time period between 0-
60min. The percent degradation of RIF was found to be increased from 2.42, 7.51, 10.19 and 13.35 in the 
time period of 15, 30, 45, and 60min respectively. The percent formation of 3FRSV was shown as 2.35, 
7.29, 9.89 and 12.96 at 15, 30, 45 and 60min respectively. 
Table :29 Percent degradation of rifampicin alone in pH 1.2 buffer(F) 
 
TIME 
(min) 
Percent degradation of RIF 
MEAN ±S.D 
TRIAL1 TRIAL2 TRIAL3 
0 - - - - 
15 2.55 2.42 2.29 2.42±0.130 
30 8.67 7.51 6.66 7.51±1.009 
45 11.40 9.12 10.17 10.19±1.141 
60 13.38 12.34 11.26 13.35±1.060 
 
 
  
Fig:24 Percent degradation of rifampicin alone in pH 1.2 buffer 
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Table :30 Percent formation of metabolite (3FRSV) of rifampicin in RIF alone at pH 1.2 
buffer(F) 
 
 
 
TIME 
(min) 
Percent formation of 3FRSV 
MEAN ±S.D 
TRIAL1 TRIAL2 TRIAL3 
0 0 0 0 0±0.00000 
15 2.25 2.45 2.35 2.35±0.10000 
30 7.20 7.29 7.38 7.29±0.09000 
45 9.89 9.87 9.90 9.89±0.01528 
60 12.91 13.00 12.97 12.96±0.04583 
 
 
 
 
 
Fig:25  Percent formation of metabolite (3FRSV) of rifampicin in RIF alone at pH 1.2 
buffer 
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Table :31 Comparison of %degradation of rifampicin and % formation of 3FRSV in 
rifampicin alone(F) 
 
TIME(min) %Degradation  of RIF %Formation of 3FRSV 
0 0 0 
15 2.42 2.35 
30 7.51 7.29 
45 10.19 9.89 
60 13.35 12.96 
 
Dissolution stability study of rifampicin in presence of FDCat pH 1.2 buffer 
The results of dissolution stability study of RIF in the presence of FDC were shown in 
tables 32,33 and 34.  figures  26 and27 . The percent degradation of RIF in the presence of FDC 
was gradually increased from 7.96, 13.07, 16.95 and 21.40 in the time period of 15, 30, 45 and 
60min respectively. Where, the concentration of RIF in the media was decreased from 97.45 to 
76.58 (µg/ml). However, the percent degradation of RIF in the presence of FDC increased when 
compared to percentage degradation of RIF alone and this increase was statistically significant 
(P<0.05). The percent formation of 3FRSV was found to be 7.77, 12.74, 16.52 and 20.96. Hence 
the percentage formation of 3FRSV in the presence of FDC was also significantly (P<0.05) 
increased when compared with RIF alone.  
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Table :32 Percent degradation of rifampicin in presence of FDCat pH 1.2buffer(F0) 
 
TIME 
(min) 
Percent degradation of RIF 
MEAN ±S.D 
TRIAL1 TRIAL2 TRIAL3 
0 - - - - 
15 7.97 8.94 8.02 7.97±0.5462 
30 13.08 13.02 13.12 13.07±0.0503 
45 16.94 16.95 16.96 16.95±0.01 
60 21.45 21.43 21.41 21.40±0.02 
 
 
 
 
Fig:26 Percent degradation of rifampicin in presence of FDCat pH 1.2buffer 
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Table: 33 Percent formation of metabolite (3FRSV) of rifampicin in RIF+FDC mixture (F0) 
 
TIME 
(min) 
Percent formation of 3FRSV 
MEAN ±S.D 
TRIAL1 TRIAL2 TRIAL3 
0 0 0 0 0 
15 7.70 7.80 7.81 7.77±0.060830 
30 12.70 12.72 12.78 12.74±0.041630 
45 16.50 16.58 16.48 16.52±0.052920 
60 20.80 20.82 20.96 20.86±0.087180 
 
 
 
 
Fig:27 . Percent formation of metabolite (3FRSV) of rifampicin in RIF+FDC mixture 
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Table: 34 Comparison of %degradation of rifampicin and % formation of 3FRSV in 
RIF+FDC mixture 
 
TIME %Degradation  of RIF %Formation of 3FRSV 
0 - - 
15 7.97 7.77 
30 13.07 12.74 
45 16.95 16.52 
60 21.40 20.86 
 
 
Dissolution stability study of rifampicin with PLGA 1:1 ratio at ph 1.2 
The results of dissolution stability study of RIF with plga 1:1 ratio.The percentage 
degradation of RIF was increased gradually from, 1.92,6.51,8.19and 11.35  in the time period of 
15, 30, 45 and 60mins respectively. Hence, it was indicated that the percentage degradation of 
RIF caused by plga 1:1was reversed significantly (P<0.05). The percentage formation of 3FRSV 
was also decreased significantly (P<0.05) when compared with percentage formation of 3FRSV 
in RIF+PLGA 1; 1ratio mixture. The concentrations of 3FRSV were found to be be1.42, 5.51, 
7.19and10.96. Addition of plga 1:1did not cause much change in the degradation of FDC (Table 
35, 36 and 37 and Figure28 and 29.) 
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Table: 35 Percent degradation of rifampicin in rifampicin +plga1:1 ratio at pH 1.2buffer 
(F1) 
 
TIME 
(min) 
Percent degradation of RIF 
MEAN ±S.D 
TRIAL1 TRIAL2 TRIAL3 
0 - - - - 
15 1.91 1.89 1.92 1.98±0.130 
30 6.50 6.49 6.50 5.12±1.009 
45 8.16 8.19 8.19 8.19±1.141 
60 11.30 11.35 11.35 11.35±1.060 
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Table :36 Percent formation of metabolite (3FRSV) of rifampicin in RIF+PLGA1:1ratio 
mixture(F1) 
 
TIME 
(min) 
Percent formation of 3FRSV 
MEAN ±S.D 
TRIAL1 TRIAL2 TRIAL3 
0 0 0 0 0 
15 1.40 1.42 1.42 1.42±0.130 
30 5.50 5.50 5.51 4.12±1.009 
45 7.19 7.20 7.19 7.19±1.141 
60 10.96 10.95 10.96 10.96±0.04583 
    
 
                 
                                                                    Fig:29 
 
 
0
2
4
6
8
10
12
0 10 20 30 40 50 60 70
%
 f
o
rm
a
ti
o
n
 o
f 
3
 f
rs
v
time(mins)
% Formation of 3 frsv
109 
 
Table: 37 Comparison of %degradation of rifampicin and % formation of 3FRSV in 
RIF+PLGA1:1 ratio mixture (F1) 
 
TIME %Degradation  of RIF %Formation of 3FRSV 
0 - - 
15 1.92 1.42 
30 6.51 5.51 
45 8.19 7.19 
60 11.35 10.96 
 
Dissolution stability study of rifampicin with PLGA 1:2 ratio at ph 1.2 
The results of dissolution stability study of RIF with plga 1:2 ratio.The percentage 
degradation of RIF was increased gradually from 1.12, 5.51, 7.19and9.35 in the time period of 
15, 30, 45 and 60mins respectively. Hence, it was indicated that the percentage degradation of 
RIF caused by plga 1:2was reversed significantly (P<0.05) . The percentage formation of 3FRSV 
was also decreased significantly (P<0.05) when compared with percentage formation of 3FRSV 
in RIF+PLGA 1; 2ratio mixture. The concentrations of 3FRSV were found tobe 1.10, 4.51, 6.19 
and8.35. Addition of plga 1:2did not cause much change in the degradation of FDC (Table 38, 
39 and 40 and Figure30 and 31). 
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Table: 38 Percent degradation of rifampicin in rifampicin +plga1:2 ratio at pH 1.2buffer 
(F2) 
 
TIME 
(min) 
Percent degradation of RIF 
MEAN ±S.D 
TRIAL1 TRIAL2 TRIAL3 
0 - - - - 
15 1.12 1.01 1.12 1.12±0.130 
30 5.51 5.50 5.50 3.85±1.009 
45 7.19 7.20 7.19 6.9±1.141 
60 9.34 9.35 9.35 9.5±1.060 
 
 
 
                     
  
                                                              Fig: 30 
 
0
1
2
3
4
5
6
7
8
9
10
0 20 40 60 80
%
 d
e
g
ra
d
a
ti
o
n
 o
f 
ri
fa
m
p
ic
in
time(mins)
% Degradation 
111 
 
Table: 39 Percent formation of metabolite (3FRSV) of rifampicin in RIF+PLGA1:2ratio 
mixture (F2) 
 
TIME 
(min) 
Percent formation of 3FRSV 
MEAN ±S.D 
TRIAL1 TRIAL2 TRIAL3 
0 0 0 0 0 
15 1.10 1.09 1.10 1.10±0.130 
30 3.51 4.00 3.51 3.5±1.009 
45 5.9 5.0 5.9 5.9±1.141 
60 8.34 8.35 8.35 8.35±0.04583 
 
 
                
                                                              Fig: 31 
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Table: 40 Comparison of %degradation of rifampicin and % formation of 3FRSV in 
RIF+PLGA1:2 ratio mixture (F2) 
 
TIME %Degradation  of RIF %Formation of 3FRSV 
0 - - 
15 1.12 1.10 
30 5.51 4.51 
45 7.19 6.19 
60 9.35 8.35 
 
Dissolution stability study of rifampicin with PLGA 1:3 ratio at ph 1.2 
The results of dissolution stability study of RIF with plga 1:3 ratio.The percentage 
degradation of RIF was increased gradually from 0.59, 3.51, 5.19and 7.35 in the time period of 
15, 30, 45 and 60mins respectively. Hence, it was indicated that the percentage degradation of 
RIF caused by plga 1:3was reversed significantly (P<0.05) . The percentage formation of 3FRSV 
was also decreased significantly (P<0.05) when compared with percentage formation of 3FRSV 
in RIF+PLGA 1;3ratio mixture. The concentrations of 3FRSV were found to be 0.09,2.51,4.19 
and 6.35. Addition of plga 1:3did not cause much change in the degradation of FDC (Table 
41,42 and 43 and Figure32 and 33 ). 
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Table: 41 Percent degradation of rifampicin in rifampicin +plga1:3 ratio at pH 1.2buffer 
(F3) 
 
TIME 
(min) 
Percent degradation of RIF 
MEAN ±S.D 
TRIAL1 TRIAL2 TRIAL3 
0 - - - - 
15 0.59 0.58 0.57 1.09±0.130 
30 3.0 2.85 2.85 2.85±1.009 
45 5.20 5.19 5.19 5.19±1.141 
60 7.34 7.35 7.35 7.35±1.060 
 
 
 
                 
                                                       Fig: 32 
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Table: 42 Percent formation of metabolite (3FRSV) of rifampicin in RIF+PLGA1:3ratio 
mixture (F3) 
 
TIME 
(min) 
Percent formation of 3FRSV 
MEAN ±S.D 
TRIAL1 TRIAL2 TRIAL3 
0 0 0 0 0 
15 0.09 0.08 0.09 1.01±0.130 
30 2.51 2.50 2.51 2.51±1.009 
45 4.19 4.20 4.19 4.19±1.141 
60 6.35 6.34 6.35 6.35±0.04583 
 
 
                  
                                                                 Fig: 33 
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Table: 43 Comparison of %degradation of rifampicin and % formation of 3FRSV in 
RIF+PLGA1:3 ratio mixture (F3) 
 
TIME %Degradation  of RIF %Formation of 3FRSV 
0 - - 
15 0.59 0.09 
30 3.51 2.51 
45 5.19 4.19 
60 7.35 6.35 
 
Dissolution stability study of rifampicin with plga 1:1 ratio in the presence of fdc at pH 1.2 
buffer 
 
The results of dissolution stability study of RIF with plga 1:1 ratio in the presence of 
FDC at pH 1.2 buffer was shown Tables ,  and  and Figures ,  and . The percentage degradation 
of RIF was increased gradually from 4.97, 11.31, 14.53 and 18.09 in the time period of 15, 30, 
45 and 60mins respectively. Hence, it was indicated that the percentage degradation of RIF 
caused by FDC was reversed significantly (P<0.05) by the addition of PLGA 1:1 ratio . The 
percentage formation of 3FRSV was also decreased significantly (P<0.05) when compared with 
percentage formation of 3FRSV in RIF+FDC mixture. The concentrations of 3FRSV were found 
to be 4.82, 10.96, 14.07 and 17.52. Addition of1:1 ratio of plga  did not cause much change in 
the degradation of FDC (Table 44,45 and 46 and Figure34 and 35 ). 
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Table: 44 Percent Degradation of rifampicin with 1:1 PLGA in the presence of FDC at pH 
1.2 buffers (F4) 
 
TIME 
(min) 
Percent degradation of RIF 
MEAN ±S.D 
TRIAL1 TRIAL2 TRIAL3 
0 - - - - 
15 4.95 4.99 4.97 4.97±0.02 
30 11.37 11.35 11.22 11.31±0.08 
45 14.56 14.52 14.49 14.53±0.035 
60 18.07 18.10 18.10 18.09±0.017 
 
 
 
 
Fig: 34 Percent Degradation of rifampicin with 1:1 PLGA in the presence of FDCat pH 1.2 
buffers 
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Table: 45 Percentage formation of metabolite (3FRSV) of rifampicin with 1:1 PLGAin the 
presence of FDCat pH 1.2 buffers (F4) 
 
TIME 
(min) 
Percent formation of 3FRSV 
MEAN ±S.D 
TRIAL1 TRIAL2 TRIAL3 
0 0 0 0 0 
15 4.79 4.81 4.86 4.82±0.03606 
30 10.96 10.95 10.97 10.96±0.01000 
45 14.0 14.09 14.12 14.07±0.06245 
60 17.48 17.51 17.57 17.52±0.04583 
 
 
 
 
Fig: 35 Percentage formation of metabolite (3FRSV) of rifampicin with 1:1 PLGA in the 
presence of FDCat pH 1.2 buffers 
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Table: 46 Comparison of %degradation of RIF and % formation of 3FRSV in the mixture 
of rifampicin PLGA NPS in 1:1 ratio along with FDC (F4) 
 
TIME %Degradation  of RIF %Formation of 3FRSV 
0 - - 
15 4.97 4.82 
30 11.31 10.96 
45 14.53 14.07 
60 18.09% 17.52 
 
 
Dissolution stability study of rifampicin with plga 1:2 ratio in the presence of fdc at pH 1.2 
buffers 
 
The results of dissolution stability study of RIF with PLGA 1:2 ratio in the presence of 
FDC at pH 1.2 buffer was shown in Tables ,  and  and Figures ,  and . The percent degradation of 
RIF was increased gradually from 3.97, 9.20, 11.23 and 14.29 in the time period of 15, 30, 45 
and 60mins respectively. The percent degradation of RIF was decreased significantly (p<0.01) 
with increase in concentration of PLGA 1:1 to 1:2.  The percent formation of 3FRSV was also 
decreased significantly (p<0.01) with increased concentration of plga. The values were 3.85, 
8.92, 10.89 and 13.86 in the time period of 15, 30, 45 and 60mins respectively. Increase in 
concentration of plga 1:2 ratio did not cause much change in the degradation of FDC (Table 
47,48and 49 and Figure36 and 37 ). 
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Table: 47 Percent degradation of rifampicin in rifampicin PLGA 1:2 NPS in the presence 
of FDC at pH 1.2 buffer (F5) 
 
TIME 
(min) 
Percent degradation of rifampicin 
MEAN ±S.D 
TRIAL1 TRIAL2 TRIAL3 
0 - - - - 
15 4.07 3.96 3.79 3.97±0.14 
30 9.23 9.19 9.20 9.20±0.02 
45 11.29 11.25 11.17 11.23±0.06 
60 14.37 14.32 14.40 14.29±0.04 
 
 
 
 
Fig: 36 Percent degradation of rifampicin in rifampicin PLGA 1:2 NPS in the presence of 
FDC at pH 1.2 buffer 
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Table: 48 Percentage formation of metabolite (3FRSV) of rifampicin with 1:2 PLGA in the 
presence of FDCat pH 1.2 buffers 
 
 
TIME 
(min) 
Percent formation of 3FRSV 
MEAN ±S.D 
TRIAL1 TRIAL2 TRIAL3 
0 0 0 0 0 
15 3.80 3.81 3.94 3.85 
30 8.90 8.91 8.95 8.92 
45 10.81 10.87 10.99 10.89 
60 13.83 13.85 13.90 13.86 
 
 
 
 
Fig: 37 Percentage formation of metabolite (3FRSV) of rifampicin with 1:2 PLGA in the 
presence of FDCat pH 1.2 buffers 
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Table: 49 Comparison of %degradation of RIF and % formation of 3FRSV in the mixture 
of rifampicin in rifampicin PLGA 1:2 ratio along with FDC (F5) 
 
TIME(min) %Degradation  of RIF %Formation of 3FRSV 
0 - - 
15 3.97 3.85 
30 9.20 8.92 
45 11.23 10.89 
60 14.29 13.86 
 
Dissolution stability study of rifampicin with plga 1:3 ratio in the presence of fdc at pH 1.2 
buffers 
 
The result of dissolution stability study of RIF in the presence of FDC and PLGA 1:3 ratio was 
shown in Tables , and  and Figures ,  and . The percent degradation of RIF was increased 
gradually from 1.46, 4.07, 6.46 and 8.92 in the time period of 15, 30, 45 and 60mins 
respectively. The percent degradation of RIF was decreased significantly (P<0.01) with increase 
in concentration of plga 1:2 to plga 1:3 ratio.  The percent formation of 3FRSV was also 
decreased with increased significantly (P<0.01) concentration of plga. The values were 1.37, 
3.96, 6.28 and 8.67 in the time period of 15, 30, 45 and 60mins respectively. Increase in 
concentration of plga 1:3 did not cause much change in the degradation of FDC(Table 50,51 and 
52 and Figure38 and 39 ). 
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Table: 50 Percent Degradation of rifampicin in rifampicin PLGA 1:3 ratio in the presence 
of FDC at pH 1.2 buffers (F6) 
 
TIME 
(min) 
Percent degradation of rifampicin 
MEAN ±S.D 
TRIAL1 TRIAL2 TRIAL3 
0 - - - - 
15 2.15 2.17 2.12 1.46±0.025 
30 4.11 4.05 4.04 4.07±0.037 
45 6.48 6.42 6.48 6.46±0.034 
60 9.40 9.34 9.40 8.92±0.034 
 
 
 
 
Fig: 38 Percent Degradation of rifampicin in rifampicin PLGA 1:3 ratio in the presence of 
FDC at pH 1.2 buffers 
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Table: 51 Percent formation of metabolite (3FRSV) of Rifampicin in rifampicin PLGA 1:3 
ratio in the presence of FDC at pH 1.2 buffers (F6) 
 
TIME 
(min) 
Percent formation of 3FRSV 
MEAN ±S.D 
TRIAL1 TRIAL2 TRIAL3 
0 0 0 0 0 
15 1.32 1.38 1.41 1.37±0.04583 
30 3.91 3.95 4.02 3.96±0.05568 
45 6.25 6.29 6.30 6.28±0.02646 
60 8.60 8.65 8.76 8.67±0.08185 
 
 
 
Fig: 39 Percent formation of metabolite (3FRSV) of rifampicin in rifampicin PLGA 1:3 
ratio in the presence ofFDC at pH 1.2 buffers 
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Table: 52 Comparison of %degradation of RIF and % formation of 3FRSV in the mixture 
of rifampicin in rifampicin PLGA 1:3 ratio aiong with FDC (F6) 
 
TIME %Degradation  of RIF %Formation of 3FRSV 
0 - - 
15 1.46 1.37 
30 4.07 3.96 
45 6.46 6.28 
60 8.92 8.67 
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8.10. Table :53 COMPARITIVE % DEGRADATION 
 
 
Fig: 40 
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% (F) DEGRADATION OF 
RIFAMPICIN
%(F0) degradation 
%(F1) degradation
%(F2)degradation
%(F3)degradation
%(F4)degradation
%(F5)Degradation 
Time RIF 
ALONE 
RIF+FDC RIF+PLG
A 1:1 
RIF+PLG
A 1:2 
RIF+PLG
A 1:3 
RIF+PLGA 
1:1+FDC 
RIF+PLG
A 
1:2+FDC 
RIF+PLG
A 
1:3+FDC 
0 0 0 0 0 0 0 0 0 
15 2.42±0.130 7.97±0.546 1.92±0.130 1.12±0.3 0.59±0.513 4.97±0.02 3.97±0.14 1.46±0.025 
30 7.51±1.009 13.07±0.05
0 
6.51±1.009 5.51±1.00
9 
3.51±0.513 11.31±0.08 9.20±0.02 4.07±0.037 
45 10.19±1.141 16.95±0.01 8.19±1.141 7.19±1.14
1 
5.19±0.208 14.53±0.35 11.23±0.0
6 
6.46±0.034 
60 13.35±1.060 21.40±0.02 11.35±1.06
0 
9.35±1.06
0 
7.35±0.513 18.09±0.017 14.29±0.0
4 
8.92±0.034 
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8.11. Table: 54 COMPARITIVE % FORMATION OF 3 FRSV 
 
 
                                                                Fig: 41 
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(F)formation of metabolite 
(3FRSV) of rifampicin 
%(F0)FORMATION OF  FRSV
%(F1) formatiom frsv
%(F2)formation frsv
%(F3)formation frsv
% (F4)formation of frsv
%(F5)Formation of FRSV
%(F6)Formation of FRSV
Time RIF 
ALONE 
RIF+FDC RIF+PLG
A 1:1 
RIF+PLG
A 1:2 
RIF+PL
GA 1:3 
RIF+PLGA 
1:1+FDC 
RIF+PLG
A 
1:2+FDC 
RIF+PLGA 
1:3+FDC 
0 0 0 0 0 0 0 0 0 
15 2.35±1.00
0 
7.77±0.060 1.42±0.130 1.10±0.3 0.09±0.5
13 
4.82±0.036 3.85±0.14 1.37±0.045 
30 7.29±0.09
0 
12.74±0.04
1 
5.51±1.009 4.51±1.009 2.51±0.5
13 
10.96±0.010 8.92±0.02 3.96±0.055 
45 9.89±0.01
5 
16.52±0.05
2 
7.19±1.141 6.19±1.141 4.19±0.2
08 
14.07±0.062 10.89±0.06 6.28±0.026 
60 12.96±0.0
45 
20.86±0.08
7 
10.35±1.06 8.35±1.060 6.35±0.5
13 
17.52±0.045 13.86±0.04 8.67±0.081 
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Chromatograms of GroupI animals (Rifampicin alone): 
 
  0.5 hr              1.0 hr 
 
                        
                                              
                       
 
 
      
1.5hr      2.0hr 
 
             
 
 
 
 
 
 
 
 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 30397 4451 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 6513 724 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 36911 5283 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 47043 15198 
128 
 
2.5hr                    3.0hr 
 
                          
 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 66585 23160 
 
 
3.5hr                                 4.0hr 
 
                              
 
 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 56452 36911 
 
 
 
 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 62966 30397 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 51386 42977 
129 
 
5.0hr                         6.0hr 
 
                          
 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 38358 47043 
 
 
8.0hr                10.0hr 
 
                        
 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 18817 29673 
  
 
 
 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 31568 41977 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 9408 15922 
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12.0hr                               24.0hr 
 
                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 2895 724 
131 
 
Chromatograms of GroupII (Rifampicin+FDC) 
0.5 hr            1.0hr 
             
 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 34740 6513 724 
 
1.5hr          2.0hr 
 
             
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 34740 34016 12303 
 
 
 
 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 38358 27504 5790 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 2967
3 
42700 20264 
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2.5hr              3.0hr 
                           
 
 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 27502 60071 29673 
 
 
                                 3.5hr                        4.0hr 
       
 
 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 20988 51386 46320 
 
 
 
 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 24607 57176 39806 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 18817 46320 54381 
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         5.0hr                                      6.0hr 
           
 
 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 11580 34740 58623 
 
 
                         8.0hr                           10.0hr 
    
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 7961 17370 37635 
 
 
 
 
 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 11219 28950 51386 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 5066 8684 18817 
134 
 
 
12.0hr                                                  24.0hr 
                 
 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 3618 2896 1448 
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Chromatograms of GroupIII animals (Rifampicin + PLGA): 
 
  0.5 hr                     1.0 hr 
 
                                
 
 
 
      
 
                         1.5hr                               2.0hr 
 
                            
 
 
 
 
 
 
 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 9513 424 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 3397 4151 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 39911 4983 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 44043 12198 
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2.5hr                   3.0hr 
 
                            
 
 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 69585 20160 
 
3.5hr                                 4.0hr 
 
                              
 
 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 59452 33911 
 
 
 
 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 65966 27397 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 54386 39977 
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5.0hr                               6.0hr 
 
                         
 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 35358 44043 
 
8.0hr                    10.0hr 
 
                          
 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 21817 26673 
  
 
 
 
 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 34568 38977 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 9708 12922 
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12.0hr                              24.0hr 
 
                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RETENTION 
TIME(MIN) 
12.231 12.578 
AREA 3195 694 
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Chromatograms of GroupIVanimals (RIF+FDC+PLGA) 
 
   0.5 hr      1.0hr 
            
 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 35463 15922 742 
 
 
1.5hr      2.0hr 
   
                                
 
 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 35463 60795 5066 
 
 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 39806 47767 2714 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 29673 73098 9408 
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2.5hr          3.0hr 
        
 
 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 28225 76718 14475 
 
 
 
    3.5hr           4.0hr 
 
             
 
 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 22436 73822 21712 
 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 25331 75270 18817 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 19541 70921 25331 
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          5.0hr                6.0hr 
 
                             
 
 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 13027 66585 28950 
 
8.0hr                         10.0hr 
 
    
 
 
  
 
 
 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 10856 60795 24607 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 18817 49215 8684 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 5790 28950 9408 
142 
 
12.0 hr       24.0hr 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RETENTION 
TIME(MIN) 
3.586 12.231 12.578 
AREA 5428 724 742 
143 
 
Table: 55 Peak area of rifampicin in Group I animals at various time intervals; n=6 
   
0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 5.0 6.0 8.0 10.0 12.0
 7273.5 28950 35463 49215 73099 64413 53557 49938 36911 34740 20948 8685 4342
 4342 31161 38358 46320 64413 62242 55728 57176 39806 33292 21712 7237 2171
 5066 28226 36187 47767 62966 63690 55005 48491 36186 31121 14475 10856 14475
 7961 32568 39082 49938 71651 60795 59347 47043 40530 32568 16646 79691 4342
 8685 29673 34740 44872 68032 57900 57900 54241 37635 30397 14475 11580 3618
 5790 31845 37635 43425 66585 62242 57176 51386 39082 28950 17370 10132 1447
 
Table: 56 Peak area of 3FRSV in Group I animals at various time intervals; n=6 
 
0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 5.0 6.0 8.0 10.0 12.0
362 2171 7237 13389 21712 28950 36187 43425 49215 40530 28950 13389 362
1086 6514 14475 19541 24607 31845 35463 41977 46320 43425 30397 19541 1086
434 3618 10132 14475 20988 29674 34740 41254 47767 41254 28226 14475 434
1013 5066 11580 13751 25331 31121 39082 44148 49939 39806 31121 13751 1013
282 2895 9409 16646 22436 28226 38358 44872 44872 44149 27502 16646 282
282 5790 12304 14330 23884 32568 37635 40530 43425 42701 31845 14330 282
 
 
 
 
                                                   Table: 57  Peak area of rifampicin in Group II animals at 
various time intervals; n=6 
 
 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 5.0 6.0 8.0 10.0 12.0
 7237 30397 38359 43425 61518 56452 54281 44872 33292 27502 15922 5790 2171
 4342 28950 31121 41977 58623 57900 48491 47767 36187 30397 18817 1158 3619
 5066 26778 29674 41253 56452 55728 49938 43425 34016 28226 16646 7961 1447
 7961 24607 33292 44148 60071 58623 51386 49215 35463 29673 18093 6513 4342
144 
 
 8685 26778 34740 44872 57176 55005 52833 44149 32569 30397 14475 9408 724
 5790 26055 39082 40530 62966 59347 50662 48491 36911 27502 20265 7237 5066
 
 
Table: 58 Peak area of 3FRSV in Group II animals at various time intervals; n=6 
 
0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 5.0 6.0 8.0 10.0 12.0
362 5066 11580 18817 28950 39082 44872 57900 62966 54281 36187 18094 724
1085 6514 13027 21712 30397 44872 47767 54281 54281 48491 40530 19541 2171
434 4342 10856 19541 28226 41253 43425 49215 56452 49938 37635 17370 2171
1013 7237 13751 20989 31121 35463 49215 47043 60795 51386 39082 2026 724
287 6514 13027 18094 27502 37635 44149 57900 57538 52833 36911 16646 287
287 5066 11580 22436 31845 40530 48491 48491 58623 50662 39806 20989 287
                                    
 
 
                                              Table: 59  Peak area of rifampicin in Group III animals at 
various time intervals; n=6 
Time(h) 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 5.0 6.0 8.0 10.0 12.0 24.0
Peak 
area 
1 9273.5 58950 65463 79215 93099 94413 83557 79938 66911 64740 50948 10685 7342 
2 6342 61161 68358 76320 94413 92742 85728 87176 69806 63292 51712 9237 5171 
3 7066 58226 66187 77767 92966 93690 85005 78491 66186 61121 44475 40856 44475 
4 9961 62588 69082 79938 91651 98795 89347 77043 60530 64568 46646 109691 7342 
5 10685 32673 37740 47872 98032 60900 87900 84241 67635 60397 44475 14580 7618 
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                                 Table: 60    Peak area of 3FRSVin Group III animals at various time 
intervals; n=6 
 
 
6 7790 34845 39635 46425 99587 65245 87176 81386 69082 58950 47370 13132 4447 
Time(h) 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 5.0 6.0 8.0 
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                                     Table: 61   Peak area of rifampicin in Group IV animals at various 
time intervals; n=6 
 
0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 5.0 6.0 8.0 10.0 12.0
14475 47044 60071 76717 75994 74546 73099 70204 65861 57900 46320 28226 13389
17370 48491 61518 70204 77441 75994 74546 71651 65137 63690 54281 29674 19541
15199 46320 59347 75270 75270 73822 72375 69480 66585 58623 44148 27502 14475
16646 49215 62242 73099 78165 76715 75270 72375 70927 62966 49938 30397 13751
13751 45596 58624 71651 74546 73099 71651 68756 64413 59345 53557 26778 16646
17370 49939 62966 73822 78889 77441 75993 73099 65137 62242 50662 31121 14330
                                           Table: 62 Peak area of 3FRSV in Group IV animals at various 
time intervals; n=6 
 
0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 5.0 6.0 8.0 10.0 12.0
Peak 
area 
 
1 162 1771 4237 10389 18712 25950 33187 40425 46215 37530 25950 
2 786 3514 11475 16541 21607 28845 32463 38977 43320 40425 27397 
3 134 1618 7132 11475 17988 26674 31740 38254 44767 38254 25226 
4 713 2066 8580 10751 23331 28121 36082 41148 46939 36806 29121 
5 182 1895 6409 13646 19436 25226 35358 41872 43872 43949 24502 
6 182 2790 9304 9330 20884 29568 34635 37530 40425 39701 28845 
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362 1447 4342 8685 18817 18094 20989 24607 27502 23883 20988 8685 362
1086 2895 5790 7238 12303 19541      22436                                                                                                                        26055 30397 25331 21712 7238 1086
435 724 3619 10856 15198 17370 20265 23884 28226 23160 14475 10856 434
1013 3619 6514 79691 17370 20265 23160 26779 29673 26055 16646 79691 1013
287 2895 2895 11580 13751 16646 19541 23160 30397 22436 14475 11580 287
287 1448                                                                                                                         7238 10133 11580 20989 23884 27503 27503 26779 17370 10133 287
   
 
 
                                    Table: 63 Plasma concentration of rifampicin in Group I animals at 
various time intervals; n=6 
 
Time(h)                                           0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 5.0 6.0 8.0 10.0 
 1.0 4.0 4.9 6.8 10.1 8.9 7.4 6.9 5.1 4.8 2.9 1.2 
 0.6 4.3 5.3 6.4 8.9 8.6 7.7 7.9 5.5 4.6 3.0 1.0 
 0.7 3.9 5.0 6.6 8.7 8.8 7.6 6.7 5.0 4.3 2.0 1.5 
 1.1 4.5 5.4 6.9 9.9 8.4 8.2 6.5 5.6 4.5 2.3 1.1 
 1.2 4.1 4.8 6.2 9.4 8.0 8.0 7.5 5.2 4.2 2.0 1.6 
 0.8 4.4 5.2 6.0 9.2 8.6 7.9 7.1 5.4 4.0 2.4 1.4 
Mean±S.E.M 0.9±0.09 4.2±0.96 5.1±0.96 6.5±0.14 9.3±0.22 8.6±0.13 7.8±0.11 7.1±0.21 5.3±0.09 4.4±0.11 2.5±0.17 1.3±0.09 0.4±0.07
 
Table: 64 Plasma concentration of 3FRSV in Group I animals at various time intervals; 
n=6 
 
0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 5.0 6.0 8.0 10.0 
 0.05 0.3 1.0 1.85 3.0 4.0 5.0 6.0 6.8 5.6 4.0 1.85 
 0.15 0.9 2.0 2.7 3.4 4.4 4.9 5.8 6.4 6.0 4.2 2.7 
 0.06 0.5 1.4 2.0 2.9 4.1 4.8 5.7 6.6 5.7 3.9 2.0 
 0.14 0.7 1.6 1.9 3.5 4.3 5.4 6.1 6.9 5.5 4.3 1.9 
 0.05 0.4 1.3 2.3 3.1 3.9 5.3 6.2 6.2 6.1 3.8 2.3 
 0.15 0.8 1.7 1.98 3.3 4.5 5.2 5.6 6.0 5.9 4.4 1.98 
Mean±S.E.M 0.1±0.02 0.6±0.09 1.5±0.14 2.1±0.13 3.2±0.09 4.2±0.09 5.1±0.09 5.9±0.09 6.5±0.14 5.8±0.09 4.1±0.09 2.1±0.13 
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                               Table: 65  Plasma concentration of rifampicin in Group II animals at 
various time intervals; n=6 
 
0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 5.0 6.0 8.0 10.0 
 1.0 4.2 5.3 6.0 8.5 7.8 7.5 6.2 4.6 3.8 2.2 0.8 
 0.6 4.0 4.3 5.8 8.1 8.0 6.7 6.6 5.0 4.2 2.6 1.6 
 0.7 3.7 4.1 5.7 7.8 7.7 6.9 6.0 4.7 3.9 2.3 1.1 
 1.1 3.4 4.6 6.1 8.3 8.1 7.1 6.8 4.9 4.1 2.5 0.9 
 1.2 3.7 4.8 6.2 7.9 7.6 7.3 6.1 4.5 4.2 2.0 1.3 
 0.8 3.6 5.4 5.6 8.7 8.2 7.0 6.7 5.1 3.8 2.8 1.0 
Mean±S.E.M 0.9±0.09 3.8±0.11 4.7±0.21 5.9±0.09 8.3±0.14 7.9±0.09 7.1±0.11 6.4±0.13 4.8±0.09 4.0±0.77 2.4±0.11 1.2±0.11 
 
 
 
Table: 66 Plasma concentration of 3FRSV in Group II animals at various time intervals; 
n=6 
0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 5.0 6.0 8.0 10.0 
 0.05 0.7 1.6 2.6 4.0 5.4 6.2 8.0 8.7 7.0 5.0 2.5 
 0.15 0.9 1.8 3.0 4.2 6.2 6.6 7.5 7.5 7.5 5.6 2.7 
 0.06 0.6 1.5 2.7 3.9 5.7 6.0 6.8       7.8 7.3 5.2 2.4 
 0.14 1.0 1.9 2.9 4.3 4.9 6.8 6.5 8.4 6.7 5.4 2.8 
 0.05 0.9 1.8 2.5 3.8 5.2 6.1 8.0 7.9 7.1 5.1 2.3 
 0.15 0.7 1.6 3.1 4.4 5.6 6.7 6.7 8.1 6.9 5.5 2.9 
Mean±S.E.M 0.1±0.02 0.8±0.06 1.7±0.06 2.8±0.09 4.1±0.09 5.5±0.18 6.4±0.13 7.2±0.27 8.1±0.17 7.1±0.11 5.3±0.09 2.6±0.09 
149 
 
 
Table: 67 Plasma concentration of rifampicin in Group III animals at various time 
intervals; n=6 
 
 
 
 
 
 
 
 
 
                                    Table: 68  Plasma concentration of 3FRSV in Group III animals at 
various time intervals; n=6 
 
Time(h) 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 5.0 6.0 8.0 10.0
Peak 
area 
 
1 1.8 5.1 5.9 7.8 11.1 9.9 8.4 7.9 6.1 5.8 3.9 
2 1.8 5.0 6.3 7.4 9.9 9.6 8.7 7.9 6.5 5.6 4.0 
3 1.6 5.3 6.0 7.7 9.7 9.5 8.6 7.7 6.0 5.3 3.0 
4 1.7 4.9 6.4 7.9 10.9 9.4 9.2 7.5 6.6 5.5 3.3 
5 1.7 5.5 5.8 7.2 10.4 9.0 9.0 8.5 6.2 5.2 3.0 
6 1.8 5.4 6.2 7.0 10.2 9.6 8.9 8.1 6.4 5.0 3.4 
Mean+SEM 1.9± 
0.09 
5.2± 
0.96 
 
6.1± 
0.96 
7.5± 
0.14 
10.3± 
0.22 
9.6± 
0.13 
8.8± 
0.11 
8.1± 
0.21 
6.3± 
0.09 
4.4± 
0.11 
 
3.5± 
0.17 
2.3
0.09
Time(h) 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 5.0 6.0 8.0
Peak 
area 
 
1 0.05 0.2 1.0 0.85 2.0 2.0 4.0 5.0 5.8 4.6 3.0
2 0.15 0.4 1.0 1.7 2.4 2.4 3.9 4.8 5.4 5.0 3.2
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                       Table: 69    Plasma concentration of rifampicin in Group IV animals at 
various time intervals; n=6 
 
 
Table: 70 Plasma concentration of 3FRSV in Group IV animals at various time intervals; 
n=6 
 
0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 5.0 6.0 8.0 10.0 
3 0.06 0.6 2.0 1.0 1.9 2.1 3.8 4.7 5.6 4.7 2.9
4 0.14 0.6 1.4 0.9 2.5 2.3 3.4 5.1 5.9 4.5 3.3
5 0.05 0.3 1.6 1.3 2.1 2.9 3.3 5.2 5.2 5.1 2.8
6 0.15 0.7 1.3 0.98 2.3 3.5 3.2 4.6 5.0 4.9 3.4
Mean+SEM 0.1 
±0.02 
0.5±
0.09 
1.4± 
0.014 
1.1± 
0.14 
2.2± 
0.09 
3.2± 
0.09 
4.1± 
0.09 
4.9± 
0.09 
5.5± 
0.14 
4.8± 
0.09 
3.1±
0.09
0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 5.0 6.0 8.0 10.0 
2.0 6.5 8.3 10.6 10.5 10.3 10.1 9.7 9.1 8.0 6.4 3.9 
2.4 6.7 8.5 9.7 10.7 10.5 10.3 9.9 9.0 8.8 7.2 4.1 
2.1 6.4 8.2 10.4 10.4 10.2 10.0 9.6 9.2 8.1 6.1 3.8 
2.3 6.8 8.6 10.1 10.8 10.6 10.4 10.0 9.8 8.7 6.9 4.2 
1.9 6.3 8.1 9.9 10.3 10.1 9.9 9.5 8.9 8.2 7.4 3.7 
2.4 6.9 8.7 10.2 10.9 10.7 10.5 10.1 9.0 8.6 7.0 4.3 
 2.2±0.8 6.6±0.09 8.4±0.09 10.0±0.13 10.6±0.09 10.4±0.09 10.2±0.09 9.8±0.09 9.2±0.13 8.4±0.13 6.8±0.02 4.0±0.09 
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0.05 0.2 0.6 1.2 2.6 2.5 2.9 3.4 3.8 3.3 2.9 1.2 
0.15 0.4 0.8 1.0 1.7 2.7 3.1 3.6 4.2 3.54 3.0 1.0 
0.06 0.1 0.5 1.5 2.1 2.4 2.8 3.3 3.9 3.2 2.0 1.5 
0.14 0.5 0.9 1.9 2.4 2.8 3.2 3.7 4.1 3.6 2.3 1.1 
0.05 0.4 0.4 1.6 1.9 2.3 2.7 3.2 4.2 3.1 2.0 1.6 
0.15 0.2 1.0 1.4 1.6 2.9 3.3 3.8 3.8 3.7 2.4 1.4 
Mean±S.E.M 0.1±0.02 0.3±0.06 0.7±0.09 1.3±0.09 2.0±0.16 2.6±0.09 3.0±0.09 3.5±0.09 4.0±0.07 3.4±0.09 2.5±0.017 1.3±0.09 
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9.1. Pharmacokinetic calculations 
Table: 71 Pharmacokinetics of rifampicin in Group I (Rifampicin alone) animals;n=6 
 
S.No Parameters 
Trials  
Mean±S.E.M 1 2 3 4 5 6 
1 Cmax(µg/ml) 10.10 8.90 8.80 9.90 9.40 9.20 9.38±0.2151 
2 Tmax(hr) 2.50 2.50 3.00 2.50 2.50 2.50 2.58±0.083 
3 AUC0-24 53.90 50.95 48.82 53.17 52.15 49.70 51.448±0.81 
4 keli(hr-1) 0.289 0.234 0.295 0.255 0.318 0.245 0.272±0.013 
5 AUC0-∞ 96.87 111.94 95.25 102.96 98.15 105.82 101.83±2.59 
6 t½ (hr) 2.182 2.251 2.196 2.150 2.140 2.324 1.942±0.098 
 
 
 
 
 
Table: 72 Pharmacokinetics of 3FRSV in Group I (Rifampicin alone) animals;n=6 
 
S.No Parameters 
Trials 
 
Mean±S.E.M 1 2 3 4 5 6 
1 Cmax(µg/ml) 6.8 6.4 6.6 6.9 6.2 6 6.48±0.1424 
2 Tmax(hr) 4.5 4.5 4.5 4.5 4.0 4.5 4.42±0.08 
3 AUC0-24 23.95 27.65 22.2 23.08 21.2 29.415 24.585±1.3 
4 keli(hr-1) 0.344 0.335 0.322 0.358 0.339 0.345 0.304±0.004 
5 AUC0-∞ 45.44 54.51 46.27 51.90 46.07 50.13 49.05±1.514 
6 t½ (hr) 1.559 2.411 1.932 2.342 1.579 2.005 1.97±0.148 
153 
 
Table: 73 Pharmacokinetics of RIF in Group II (Rifampicin in the presence of FDC); n=6 
  
S.No Parameters 
Trials 
 
Mean±S.E.M 1 2 3 4 5 6 
1 Cmax(µg/ml) 8.50 8.10 7.80 8.30 7.90 8.70 8.22±0.1424 
2 Tmax(hr) 2.50 2.5 2.50 2.50 2.50 2.50 2.5±0.0 
3 AUC0-24 36.50 40.40 34.92 39.52 35.50 41.2 38.0±1.10 
4 keli(hr-1) 0.383 0.308 0.403 0.316 0.464 0.298 0.36±0.027 
5 AUC0-∞ 58.67 66.70 54.3 65.83 52.54 70.37 61.4±2.97 
6 t½ (hr) 1.808 1.794 1.722 1.702 1.495 1.681 1.97±0.138 
 
 
 
Table: 74 Pharmacokinetics of 3FRSV in Group II (Rifampicin in the presence of FDC); 
n=6 
 
S. 
No 
Parameters 
Trials 
 
Mean±S.E.M 1 2 3 4 5 6 
1 Cmax(µg/ml) 8.7 7.5 7.8 8.4 8 8.1 8.1±0.17400 
2 Tmax(hr) 4.5 4 4.5 4.5 4 4.5 4.3±0.10540 
 
3 
AUC0-24 39.675 43.45 40.405 40.745 38.4 41.85 40.75±0.71410 
4 keli(hr-1) 0.2040 0.2047 0.2997 0.2970 0.2660 0.2636 0.255±0.0174 
5 AUC0-∞ 61.17 68.06 66.42 61.89 55.53 64.12 62.9±1.81500 
6 t½ (hr) 1.713 2.275 2.312 1.744 1.485 1.906 1.9±0.13440 
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Table: 75   Pharmacokinetics of rifampicin in Group III (Rifampicin in the presence of 
PLGA); n=6 
S.No Parameters 
Trials 
 
Mean±S.E.M 1 2 3 4 5 6 
1 
Cmax(µg/ml) 
11.10 9.90 9.80 10.90 10.40 10.20 
11.38± 
0.2151 
2 Tmax(hr) 2.86 2.85 2.86 2.86 2.86 2.87 2.865±0.003 
3 AUC0-24 97.90 90.95 88.82 97.17 96.15 89.70 97.448±0.081 
4 keli(hr-1) 0.136 0.135 0.134 0.135 0.136 0.136 0.136±0.013 
5 AUC0-∞ 161.87 16.80 16.85 160.87 160.87 160.87 161.4±2.97 
6 t½ (hr) 2.541 2.542 2.543 2.542 2.542 2.541 2.542±0.098 
 
 
 
Table: 76 Pharmacokinetics of 3FRSV in Group III (Rifampicin in the presence of PLGA); 
n=6 
S.No Parameters 
Trials 
 
Mean±S.E.M 1 2 3 4 5 6 
1 Cmax(µg/ml) 2.8 2.4 2.6 2.9 2.2 2.2 2.48±0.1424 
2 Tmax(hr) 4.61 4.60 4.60 4.61 4.62 4.61 4.62±0.008 
3 AUC0-24 3.58 3.59 3.58 3.51 3.52 3.58 3.585±1.3 
4 keli(hr-1) 0.384 6.380 0.382 0.384 0.382 384 0.384±0.044 
5 AUC0-∞ 24.44 34.51 26.27 32.90 28.07 29.13 24.05±514 
6 t½ (hr) 2.559 3.411 2.932 3.342 2.579 1.005 2.18±0.148 
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Table: 77 Pharmacokinetics of rifampicin inGroup IV (RIF+FDC+PLGA);n=6 
S.No Parameters 
Trials  
Mean±S.E.M 1 2 3 4 5 6 
1 Cmax(µg/ml) 10.6 10.7 10.4 10.8 10.3 10.9 10.62±0.09 
2 Tmax(hr) 2.0 2.50 2.00 2.50 2.50 2.50 2.33±0.1054 
3 AUC0-24 80.65 90.15 80.875 84.375 84.20 84.75 84.2±1.407 
4 keli(hr-1) 0.195 0.160 0.188 0.194 0.173 0.193 0.18±0.01 
5 AUC0-∞ 135.07 157.18 136.21 140.10 143.81 141.3 142.27±3.261 
6 t½ (hr) 3.559 4.342 3.688 3.577 4.012 3.595 3.795±0.1292 
 
Table: 78 Pharmacokinetics of 3FRSVinGroup IV (RIF+FDC+PLGA) animals;n=6 
 
S.No Parameters 
Trials  
Mean±S.E.M 1 2 3 4 5 6 
1 Cmax(µg/ml) 3.8 4.2 3.9 4.1 4.2 3.8 4.0±0.07746 
2 Tmax(hr) 4.5 4.5 4.5 4.5 4.5 4.5 4.5±0.000 
3 AUC0-24 19.45 20.15 18.71 19.99 18.9 20.85 19.68±0.33 
4 keli(hr-1) 0.406 0.405 0.472 0.422 0.481 0.491 0.446±0.016 
5 AUC0-∞ 28.81 34.12 29.17 32.72 29.92 33.87 31.44±0.98 
6 t½ (hr) 2.032 2.908 2.156 2.152 2.086 2.375 2.28±0.134 
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9.2. Pharmacokinetic parameters of rifampicin 
 Cmaxof rifampicin in RIF alone, RIF+FDC, RIF+PLGA and RIF+FDC+PLGA 
 
 The mean Cmax values of RIF in RIF alone, RIF+FDC, RIF+PLGA and RIF+FDC+PLGA 
are respectively 9.383±0.2151, 8.216±0.1424,11.38±0.2151 and 10.616±0.0945. The Cmax of RIF 
was decreased in the presence of FDC significantly (p<0.001) andCmax of RIF+FDC+PLGA 
was decreased compared to RIF+PLGA significantly (p<0.001). 
Table: 79 
Cmaxof rifampicin in RIF alone, RIF+FDC, RIF+FDC+PLGA n=6, Mean±S.E.M 
 
S.NO GROUP Cmax(µg/ml)  
1 
2 
3 
4 
RIF alone 
RIF+FDC 
RIF+PLGA 
RIF+FDC+PLGA 
 
9.38±0.2151 
8.22±0.1424 
11.38±0.2151 
10.616±0.0945 
 
a=p<0.001, b=p<0.001, c=p<0.001 d=p<0.001 when compared with RIF alone, RIF+FDC, 
RIF+PLGA and RIF+FDC+PLGA groups respectively followed by one way ANOVA followed 
by Tukey’s multiple comparison test. P<0.05 was considered as significant. 
Fig: 42 Cmaxof RIF alone, RIF+FDC,RIF+PLGA, RIF+FDC+PLGA 
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Tmaxof RIF in RIF alone, RIF+FDC, and RIF+FDC+PLGA 
 
The mean Tmax values of RIF, RIF+FDC,RIF+PLGA, RIF+FDC+PLGAare respectively 
2.583±0.0083, 2.5±0.00, 2.865±0.003 and 2.33±0.1054. There is no significance difference in 
Tmax of RIF alone, RIF+FDC, RIF+PLGA and RIF+FDC+PLGA 
 
Table: 80 
Tmaxof rifampicin in RIF alone, RIF+FDC, RIF+PLGA and RIF+FDC+PLGA n=6, Mean±S.E.M 
 
S.NO GROUP Tmax(hr-1) 
1 
2 
3 
4 
RIF alone 
RIF+FDC 
RIF+PLGA 
RIF+FDC+PLGA 
2.58±0.083 
2.5±0.00 
2.865±0.003 
2.33±0.1054 
 
There is no significant difference in p values of Tmaxin RIF alone, RIF+FDC,RIF+PLGA, 
RIF+FDC+PLGAfollowed by one way ANOVA followed by Tukey’s multiple comparision test. 
P<0.05 was considered as significant. 
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Fig: 43 Tmaxof rifampicin in RIF alone, RIF+FDC,RIF+PLGA and RIF+FDC+PLGA 
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AUC0-24of rifampicin in RIF alone, RIF+FDC,RIF+PLGA, RIF+FDC+PLGA 
 
The mean AUC0-24 values of RIF, RIF+FDC,RIF+PLGA RIF+FDC+PLGA are respectively 
51.448±0.8099, 38.008±1.100, 97.448±0.081 and 84.166±1.407. Auc0-24 of RIF was decreased in 
the presence of FDC significantly (p<0.001) and the AUC of RIF+FDC+PLGA was decreased 
compare to RIF+PLGA was significantly (p<0.001). 
Table: 81 
AUC0-24of rifampicin in RIF alone, RIF+FDC, RIF+FDC+PLGA n=6,Mean±S.E.M 
 
S.NO GROUP AUC0-24(µg/ml.hr) 
1 
2 
3 
4 
RIF alone 
RIF+FDC 
RIF+PLGA 
RIF+FDC+PLGA 
51.448±0.8099 
38.008±1.100 
97.448±0.081 
84.166±1.407 
 
a=p<0.001; b=p<0.001, c=p<0.001 d=p<0.001 when compared with RIF alone, 
RIF+FDC,RIF+PLGA and RIF+FDC+PLGA groups resceptivelyfollowed by one way ANOVA 
followed by Tukey’s multiple comparision test. P<0.05 was considered as significant. 
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Fig: 44 AUC0-24 of rifampicin in RIF alone, RIF+FDC,RIF+PLGA,RIF+FDC+PLGA 
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Kel(hr-1)of Rifampicin in RIF alone, RIF+FDC,RIF+PLGA,RIF+FDC+PLGA 
 
The mean Kel(hr-1) values of RIF, RIF+FDC,RIF+PLGA RIF+FDC+PLGA are respectively 
0.2726±0.0134, 0.362±0.0268, 0.136±0.013 and 0.1838±0.006.Kel of RIF was increased in the 
presence of FDC significantly (p<0.001) RIF+FDC+PLGA was increased compared to  
RIF+PLGA and this increase was significantly (p<0.001). 
Table: 82 
Kel(hr-1) of rifampicin in RIF alone, RIF+FDC,RIF+PLGA,RIF+FDC+PLGA n=6, Mean±S.E.M 
 
S.NO GROUP Kel(hr-1) 
1 
2 
3 
4 
RIF alone 
RIF+FDC 
RIF+PLGA 
RIF+FDC+PLGA 
0.2726±0.0134 
0.362±0.0268 
0.136±0.013 
0.1838±0.006 
 
a=p<0.01; b=P<0.01, b=p<0.001, c=p<0.01, c=p<0.001, d=p<0.001 when compared with RIF 
alone, RIF+FDC,RIF+PLGA and RIF+FDC+PLGA groups resceptivelyfollowed by one way 
ANOVA followed by Tukey’s multiple comparision test. P<0.05 was considered as significant 
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Fig: 45  Kel(hr-1)of rifampicin in RIF alone, RIF+FDC,RIF+PLGA,RIF+FDC+PLGA. 
 
 
160 
 
 AUC0-∞ of rifampicin in RIF alone, RIF+FDC,RIF+PLGA,RIF+FDC+PLGA 
 
The mean AUC0-∞values of RIF, RIF+FDC,RIF+PLGA,RIF+FDC+PLGA are respectively 
101.8316±2.587, 61.407±2.970,161.4±2.97 and 142.27±2.361.AUC0-∞ of RIF was decreased in 
the presence of FDC significantly (p<0.001) and AUC of RIF+FDC+PLGA was decreased 
compared to RIF+PLGA this decrease was significantly (p<0.001). 
Table: 83 
AUC0-∞of rifampicin in RIF alone, RIF+FDC,RIF+PLGA, RIF+FDC+PLGA n=6, Mean±S.E.M 
 
S.NO GROUP AUC0-∞(µg/ml.hr) 
1 
2 
3 
4 
RIF alone 
RIF+FDC 
RIF+PLGA 
RIF+FDC+PLGA 
101.8316±2.587 
61.407±2.970 
161.4±2.97142.27±2.361 
 
a=p<0.001; b=P<0.001, c=p<0.001 d=p<0.001 when compared with RIF alone, 
RIF+FDC,RIF+PLGA and RIF+FDC+PLGA groups respectivelyfollowed by one way ANOVA 
followed by Tukey’s multiple comparison test. P<0.05 was considered as significant. 
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Fig: 46 AUC0-∞of rifampicin in RIF alone, RIF+FDC,RIF+PLGA,RIF+FDC+PLGA 
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9.3. Pharmacokinetic parameters of 3FRSV 
Cmaxof 3FRSV in RIF alone, RIF+FDC,RIF+PLGA and RIF+FDC+PLGA 
 
 The mean Cmax values of 3FRSV in RIF, RIF+FDC,RIF+PLGA,RIF+FDC+PLGAare 
respectively 6.483±0.1424, 8.0808±0.174,2.48±0.1424 and 4.0±0.077. The Cmaxof RIF was 
increased in the presence of FDC significantly (p<0.001) and this increase was also seen in 
theRIF+FDC+PLGAwhen compared to RIF +PLGA significantly (p<0.001). 
Table: 84 
Cmaxof 3FRSVin RIF alone, RIF+FDC, RIF+PLGA, RIF+FDC+PLGA n=6, Mean±S.E.M 
 
 
 
 
 
 
 
 
 
a=p<0.001; b=P<0.001, c=p<0.001 d=p<0,001 when compared with RIF alone, 
RIF+FDC,RIF+PLGA and RIF+FDC+PLGA groups respectivelyfollowed by one way ANOVA 
followed by Tukey’s multiple comparison test. P<0.05 was considered as significant 
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Fig: 47 Cmaxof 3FRSV in RIF alone, RIF+FDC,RIF+PLGA,RIF+FDC+PLGA 
S.NO GROUP Cmax(µg/ml) 
1 
2 
3 
4 
RIF alone 
RIF+FDC 
RIF+PLGA 
RIF+FDC+PLGA 
6.483±0.1424 
8.0808±0.174 
2.48±0.1424 
4.0±0.077 
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Tmaxof 3FRSV in RIF alone, RIF+FDC, RIF+PLGA and RIF+FDC+PLGA 
 
The mean Tmax values of 3FRSV in RIF, RIF+FDC, RIF+PLGA, RIF+FDC+PLGAare 
respectively 4.416±0.0083, 4.33±0.1054, 4.62±0.008 and 4.5±0.001. There is no significance 
difference in Tmax of 3FRSV in RIF alone, RIF+FDC, RIF+PLGA and RIF+FDC+PLGA 
Table: 85 
Tmaxof 3FRSVin RIF alone, RIF+FDC, RIF+PLGA and RIF+FDC+PLGA n=6, Mean±S.E.M 
 
S.NO GROUP Tmax(hr-1) 
1 
2 
3 
4 
RIF alone 
RIF+FDC 
RIF+PLGA 
RIF+FDC+PLGA 
2.58±0.083 
2.5±0.004 
4.62±0.008 
4.5±0.001 
 
There is no significant difference in p values of RIF alone, RIF+FDC,RIF+PLGA, 
RIF+FDC+PLGA followed by one way ANOVA followed by Tukey’s multiple comparison test. 
P<0.05 was considered as significant 
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Fig: 48 Tmaxof 3FRSV in RIF alone, RIF+FDC,RIF+PLGA and RIF+FDC+PLGA 
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AUC0-24of 3FRSV in RIF alone, RIF+FDC,RIF+PLGA,RIF+FDC+PLGA 
The mean AUC0-24 values of 3FRSV in RIF alone, RIF+FDC,RIF+PLGA, 
RIF+FDC+PLGA are respectively 24.585±1.322, 40.754±0.7141, and 19.675±0.0311.AUC0-24of 
3FRSV was increased in the presence of FDC significantly (p<0.001) AUC was increased incase 
of RIF+PLGA+FDC compared to RIF+PLGA and this increase was significantly (p<0.001). 
Table: 86 
AUC0-24of 3FRSV in RIF alone, RIF+FDC, RIF+PLGA, RIF+FDC+PLGA n=6, Mean±S.E.M 
 
S.NO GROUP AUC0-24 (µg/ml.hr) 
1 
2 
3 
4 
RIF alone 
RIF+FDC 
RIF+PLGA 
RIF+FDC+PLGA 
24.585±1.322 
40.754±0.7141 
3.585±1.3 
19.675±0.0311 
 
a=p<0.001; b=P<0.001, c=p<0.001 d=p<0.001 when compared with RIF alone, 
RIF+FDC,RIF+PLGA and RIF+FDC+PLGA groups respectivelyfollowed by one way ANOVA 
followed by Tukey’s multiple comparison test. P<0.05 was considered as significant 
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Fig: 49 AUC0-24 of 3FRSV in RIF alone, RIF+FDC,RIF+PLGA,RIF+FDC+PLGA 
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Kel(hr-1)of 3FRSV in RIF alone, RIF+FDC,RIF+PLGA,RIF+FDC+PLGA 
 
The mean Ke(hr-1) values 3FRSV in RIF, RIF+FDC,RIF+PLGA, RIF+FDC+PLGA are 
respectively 0.3405±0.00487, 0.2558±0.0174,0.384±0.004 and 0.4461±0.01611.Kel of 3FRSV 
was decreased in the presence of FDC significantly (p<0.001) and the kel of RIF+PLGA+FDC 
was increased when compare to RIF+PLGA this increase was significantly (p<0.001).  
Table: 87 
Kel(hr-1) of 3FRSV in RIF alone, RIF+FDC, RIF+FDC+PLGA 
 
S.NO GROUP Kel(hr-1) 
1 
2 
3 
4 
RIF alone 
RIF+FDC 
RIF+PLGA 
RIF+FDC+PLGA 
0.3405±0.00487 
0.2558±0.0174 
0.384±0.004 
0.4461±0.01611 
 
a=p<0.01; b=P<0.01, c=p<0.001, d=p<0.001 when compared with RIF alone, 
RIF+FDC,RIF+PLGA and RIF+FDC+PLGA groups respectivelyfollowed by one way ANOVA 
followed by Tukey’s multiple comparison test. P<0.05 was considered as significant 
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Fig: 50 Kel(hr-1)of 3FRSV in RIF alone, RIF+FDC,RIF+PLGA, RIF+FDC+PLGA 
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 AUC0-∞ of 3FRSV in RIF alone, RIF+FDC, RIF+PLGA, RIF+FDC+PLGA 
The mean AUC0-∞values of 3FRSV of RIF, RIF+FDC, RIF+PLGA, RIF+FDC+PLGA 
are respectively 49.053±1.514, 62.865±1.815, 24.05±514 and 31.435±0.985. AUC0-∞ of 3FRSV 
was increased in the presence of FDC significantly (p<0.001) and this increase was also seen in 
RIF+FDC+PLGA a when compared to RIF+PLGA significantly (p<0.001). 
Table: 88 
AUC0-∞of 3FRSV in RIF alone, RIF+FDC, RIF+PLGA, RIF+FDC+PLGA n=6, Mean±S.E.M. 
 
S.NO GROUP AUC0-∞(µg/ml.hr) 
1 
2 
3 
4 
RIF alone 
RIF+FDC 
RIF+PLGA 
RIF+FDC+PLGA 
49.053±1.514 
62.865±1.815 
24.05±514 
31.435±0.985 
 
a=p<0.001; b=P<0.001, c=p<0.001 d=p<0.001 when compared with RIF alone, 
RIF+FDC,RIF+PLGA and RIF+FDC+PLGA groups respectivelyfollowed by one way ANOVA 
followed by Tukey’s multiple comparison test. P<0.05 was considered as significant 
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Fig: 51 AUC0-∞ of 3FRSV in RIF alone, RIF+FDC,RIF+PLGA, RIF+FDC+PLGA 
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10. DISCUSSION 
Treatment of tuberculosis remains challenge due to resistance to the drug treatment 
rifampicin, isoniazid, pyrazinamide, ethambutol, are drugs of choice due to resistance to the drug 
treatment of tuberculosis as recommended by WHO. They are administered as a fixed dose 
combination in order to avoid drug resistance to separately administered drugs. This fixed dose 
combination (FDC) is widely used in india and elsewhare due to better patient compliance, 
reduction in viable bacterial population in minimization of drug resistance. Reports indicate poor 
bioavailability of rifampicin from a number of dosage forms of rifampicin and its combination 
with INH75. This may be responsible for the treatment failure and consequent development of 
resistance. 
  Degradation of rifampicin is another issue that affects bioavailability of rifampicin. 
Rifampicin degrade in acidic condition of the stomach and the degration of rifampicin  is pH 
dependend76. Another report says the problem of poor absorption of rifampicin from 
combination products is perhaps due to increased decomposition in stomach condition and the 
decomposition of rifampicin is enhanced by presence of INH. 
 In acidic medium rifampicin hydrolyses to 3 formyl rifampicin SV (3-FRSV) and it 
undergoes air oxidation in alkaline medium to form in active quinone derivative rifampicin 
quinine, 3-FRSV precipitates in acidic condition. It shows high antimicrobial activity77 but is 
inactive in invivo (USP DI,1996). Therefore formation of 3-FRSV in the acidic condition 
environment of stomach can be an important factor affecting bioavailability of rifampicin and 
cannot be overlooked. 
   Rifampicin has been reported rapidly absorbed from the stomach however undergoes 
degradation and so results as in poor bioavailabilty of rifampicin. The normal gastric empty time 
is 2-3 hrs. several fixed dose combination of rifampicin are available however it has been 
reported that these formulation showed varied release rate of rifampicin in the stomach and so 
resulting in prolonged resisdent time in the gastric pH. 
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Any attempt that can be prevent  or minimize the degradation of rifampicin either as a 
single drug or in combination of other anti tubercular drug is therapeutically beneficial to 
overcome resistance to tuberculosis treatment and there by achive effective control of 
tuberculosis with improved bioavailabilty of rifampicin. 
Based on the above factors present study was aimed to study the decomposition effect of 
rifampicin in a pH stimulating the condition in stomach and also how rifampicin nanoparticles 
addition protects rifampicin against degradation in the gastric pH. The stability was extended to 
3 hrs considering the gastric empty time (3 hrs). 
The result of the stability indicate that  rifampicin  nanoparticles   minimizes degradation 
of rifampicin and at low level concentration rifampicin nanoparticles could reduce the rifampicin 
degradation from 2% to 12% (statistically significant; P<0.001) as the rifampicin nanoparticles  
concentration was increased the degradation of rifampicin was further reduced significantly. This 
may the probable mechanism for protective effect of rifampicin against degradation in the 
stomach. 
Rifampicin degraded 13.35% at 60min and the degradation was increased to 21.4% in the 
presence of FDC. Rifampicin nanoparticles Incorporation reduced the RIF’s degradation in the 
presence of FDC in a dose dependent manner. Maximum inhibition of degradation of RIF in the 
presence and absence of FDC was found with 1:3 ratios with rifampicin nanoparticles. Beyond 
this concentration no significant (p>0.05) inhibition of RIF degradation in presence of FDC 
(8.46%) was observed. The inhibition of RIF’s degradation in presence of FDC by rifampicin 
nanoparticles was well reflected in the percent formation of 3FRSV, the metabolite of RIF. 
Rifampicin nanoparticles dose dependently inhibit the formation of 3FRSV was observed 
with1:3 ratios of rifampicin nanoparticles. There was no significant (p>0.05) inhibit of 3FRSV 
formation (8.23%) beyond the concentration 1:3 ratio of plga (Tables 53, 54 and Figs 40, 41). 
The above findings clearly suggest that Icorporation of rifampicin nanoparticles   reduces RIF 
degradation, formation of the metabolite 3FRSV in the presence of FDC. 
 
The encapsulation efficiency and percentage yield of the nanoparticles were found 
influenced by rifampicin nanoparticles (PLGA) concentration; both parameters were increased 
with increasing  rifampicin nanoparticles( PLGA)   concentration. During the formation of 
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nanoparticles the RIF might be undergoing shift from crystallanity to amorphous in the polymer 
PLGA and therefore the increasing encapsulation efficiency and percentage yield with increase 
in PLGA concentration. The DSC thermogram showed characteristic change in the endothermic 
peak of rifampicin showing amorphous form of the drug that helps in influencing the 
encapsulation efficiency and percentage yield of nanoparticles. The particle was found smooth 
and spherical at all concentration of polymer, however with increase in size of particles as the 
concentration of PLGA increased. The particle size increased with increase in PLGA 
concentration. The particle sige of nanoparticles depend upon that techniques followed for 
preparation of nanopartilces and other factors such as the type of crosslinking agent and the 
desolvating agent used. The size of the nanoparticles ranged from 298 ± 025nm to892 ± 0.12 
nm (Table 9). An increase in particle site was evident with increase in PLGA concentration.. 
The PDI of nanoparticles ranged between 0.195 and 0.541 (Table 9) which indicates a 
homogenous dispersion of the drug; the PDI was found increased with increasing the PLGA 
concentration indicating that higher concentration of the polymer detrimental to homogenous 
dispersion of the drug. This may be another reason pointing to suggest that the particle size of the 
nanoparticles depending on the PLGA concentration. 
Surface characterstics of the nanoparticles greatly influence their intereaction with the 
biological memberane, besides the stability of nanoparticles. Zeta potential is an index of the 
stability of the nanoparticles under most conditions, the higher the absolute value of the zeta 
potential of the nanoparticles, the larger the charge on their surface, leading to stronger repulsive 
interaction between  the dispersed nanoparticles and higher stability  and more uniform size. It 
has also been demonstrated that a high potential value of above ±25mv, ensures a high energy 
barrier that stabilizes the nanosuspension (Muller R.H. et al)78. A lower zeta potential (less than 
0.25mv) observed in the formulations F2, F3, F4, F5& F6  may be another factor influencing the 
particle site of nanoparticles in these  formulations. The nano size initially formed during the 
preparation of nanoparticles formed aggregates to grow in size due to instability of the 
nanoparticles with low zeta potential which was evident in F2, F3, F4, and F5& F6. 
A variable dissolution profile of formulations F1, F2 F3, F4, F5 and F6 was observed. All 
formulations showed slow dissolution of Rifampicin. However the percentage of rifampicin 
release was highest 35% (Table 14 and fig 17) from F1, and lowest 17.2(Table 24and fig 22) from 
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F6 formulation. The percentage of rifampicin release from F2 was 31.4(Table 16 and fig 18) . 
The percentage of rifampicin release from F3 was 28 %( Table 18 and fig 19) .The percentage of 
rifampicin  release from F4 was22.4%( (Table 20 and fig 20). The percentage of rifampicin 
release from F5 was 20.4(Table 22 and fig 21). All the formulations showed zero order release 
kinetic with r2 value about 0.99. The variation in percent drug release at different time point 
intervals, in different formulations may be due to the PLGA concentration used.     The factors 
influencing the dissolution of rifampicin can be stated as follows. 1. Particle size plays as 
important role in influencing the dissolution of the drug in the environment. The particle size was 
least in F1 298 nm as compared to that in F2 495nm and F3 596nm and F4698nm, F5 859nm 
andF6 892nm. Therefore it is obvious that a higher percent of Rifampicin was released from F1 
as compared to F2 F3, F4, F5 and F6. Other factors such as pH of the environment can also 
influence the dissolution of drug. However in the present study all formulations showed slow 
dissolution which was found to be independent of pH of the environment. These observations 
suggest that PLGA nanoparticles release the drug at a rate independent of the pH of the 
environment.  
The in-vitro dissolution profile of F1, F2 F3, F4, F5 and F6 was also reflected in the 
diffusion study. The percentage drug diffused from F1 F2 F3, F4, F5 and F6 was 35%. 31, 4%, 
28%, 22.4%, 20.4%and 17.2% (Table 14, 16, 18, 20,22and24) respectively. These findings 
propose that factors particularly particle size of nanoparticles did also influenced the diffusion of 
drug which was found to be dependent upon the PLGA concentration. There was no burst release 
of drug from all the formulations and showed a near perfect zero order release of the 
nanoparticles. 
Based on the dissolution and diffusion characteristics the formulation F6 was found to be 
the ideal formulation for further in-vivo study. According to FDA guidelines a controlled release 
formulation should release 0-20% at 4 h, 15-70% at 12 h and > 85% at 24h. Accordingly a 
formulation F6 was found to satisfy the above requirement compared to F2 F3, F4, F5 and F6 as 
such the formulation F6was selected for the in-vivo pharmacokinetic study.  
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The result of in-vitro study was examined in the in-vivo study. The in-vivo study was 
limited to the influence of Rifampicin PLGA in 1:3 ratios along with FDC on the 
pharmacokinetic of RIF and FDC because PLGA at this concentration was found to inhibit RIF 
degradation in the presence of FDC to maximum. The Cmax of RIF was significantly decreased 
from 9.38-8.22µg/ml and Increased to 11.38 when rifampicin along with PLGA this was 
reversed to 10.61µg/ml by PLGA along with FDC(Table79  and Fig42 ). The bioavailability of 
the drug is normally reflected in the AUC values of the drug. The AUC(0-24) of RIF was 
significantly (p<0.001) reduced from 51.44 to 38.00 in the presence of FDC ,and increased to 
94.44 in the presence of PLGA along with rifampicin which was reverse to 84.16 by PLGA in 
the presence of FDC (Table 81 and Fig 44). Similarly there was significant difference in AUC(0-
∞) of RIF as compared to RIF +FDC and RIF+PLGA and RIF +PLGA+FDC. The AUC (0-∞) of 
RIF was 101.83 which was significantly decreased to 61.40 by FDC.164.4 when rifampicin 
along with PLGA. Rifampicin nanoparticles Incorporation reversed the AUC(0-∞) values from 
164.4 of RIF+PLGA to 142.27 of RIF +FDC+PLGA (Table 83 and Fig 46) significantly 
(p<0.001). The changes in Cmax, AUC0-24, and AUC0-∞ clearly indicate that PLGA significantly 
improve the bioavailability of RIF. Comparison of Cmax, AUC(0-24) and AUC0-∞ of RIF with that 
of 3FRSV reveal that Incorporation of Rifampicin nanoparticles PLGA  significantly inhibit the 
formation of 3FRSV, the metabolite of RIF.  
 
The Cmax of 3FRSV with RIF alone was 6.48 which was increased to 8.08 significantly 
(p<0.001) that was significantly (p<0.001) reversed to 4.0 by PLGA co administration (Table 
89and Fig 51). The AUC(0-24) of 3FRSV with RIF+FDC was 40.75and 3.58 with RIF+PLGA 
which was reduced significantly (p<0.001) to 19.67 by Incorporation of PLGA along with 
FDC(Table 91 and Fig 53). Similar pattern was observed with AUC0-∞ of 3FRSV which was 
62.86 with RIF in the presence of FDC and it was significantly (p<0.001) reduced to 31.43 with 
Incorporation of PLGA along with FDC(Table 88 and Fig 51). The Tmax of RIF was not 
significantly affected in the presence of FDC as well as with Incorporation of rifampicin 
nanoparticles . The Kel of RIF was significantly (p<0.01) influenced and decreased from 0.36hr-1 
to 0.183hr-1 by Incorporation of rifampicin nanoparticles   in the presence of FDC (Table 82 and 
Fig 45). The underlying mechanism for change in Kel value of RIF in the presence of FDC  by 
Incorporation of rifampicin nanoparticles  was not clearly understood. Presence of 3FRSV 
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formation we observed similar Kel of 3FRSV is increased significantly (p<0.01) with 
Incorporation of rifampicin nanoparticles (Table 87 and Fig 50). 
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11. CONCLUSION 
 
The present study reveals that FDC promotes degradation of rifampicin in the acidic 
environment.Incorporation of rifampicin nanoparticles in fixed dose combinations resulted more 
rifampicin concentration availability in the acidic environment for absorption. Further work in 
humans may help to understand the beneficial effects of rifampicin nanoparticles in fixed dose 
combination instead of rifampicin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
173 
 
11. REFERENCES 
 
1. Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for worldwide tuberculosis control under 
the WHO DOTS strategy. Directly observed short-course therapy. Lancet 1998;352:1886-91. 
2. Mariappan TT, Saranjit Singh. Gastrointestinal permeability studies using combinations of 
rifampicin and nucleoside analogue reverse transcriptase inhibitors in rats. Ind J Pharmacol 
2007;39:284-90. 
3. Jianfang Liu, Jin Sun, Wei Zhang, Kun Gao, Zhonggui He. HPLC determination of rifampicin and 
related compounds in pharmaceuticals using monolithic column. J Pharm Biomed Anal 
2008;46:405–09. 
4. Hemanth Kumar A. Chandra IK, Geetha R, Silambu Chelvi K, Lalitha V, Prema G. A validated high-
performance liquid chromatography method for the determination of rifampicin and desacetyl 
rifampicin in plasma and urine. Ind J Pharmacol 2004;36:231-33.  
5. Subhash Agal, Rajiv Baijal, Snehanshu Pramanik, Nikhil Patel, Parijat Gupte, Praful Kamani, 
Deepak Amarapurkar. Monitoring and management of antituberculosis drug induced 
hepatotoxicity. J Gastroenterol Hepatol 2005;20:1745-52. 
6. Heifects LB, Lindholm-Levy P. Comparison of bacterial activities of streptomycin, amikacin, 
kanamycin, and capreomycin against Mycobacteerium avium and M tuberculosis. Antimicrob 
Agents Chemother 1989;33:1298-1301. 
7. Garg RK. Classic diseases revisited: Tuberculosis of the central nervous system. Postgrad Med J 
1999;75:133-140. 
8. Mitchison DA. Mechanism of drug action in short-course chemotherapy. Bull Int Union Tuberc 
1985;65:30-7. 
9. Iseman MD, Madsen LA. Drug-resistant tuberculosis. Clin chest Med 1989;10:341-53. 
174 
 
10. Panchagnula R, Rungta S, Sancheti P, Agrawal S, Kaul C. In vitro evaluation of food effect on the 
bioavailability of rifampicin from antituberculosis fixed dose combination formulations. 
Farmaco. 2003;58:1099-1103. 
11. Acocella G. Clinical Pharmacokinetics of Rifampicin.Clin Pharmacokinet 1978;3:108-27. 
12. Peloquin CA, Namdar R, Singleton MD, Nix DE.  Pharmacokinetics of Rifampin Under Fasting 
Conditions, With Food, and With Antacids. Chest 1999;115:12-18. 
13. Satish Balkrishna Bhise, Sevukarajan Mookkan. Formulation and Evaluation of Novel FDCs of 
Antitubercular Drugs. J Pharm Res 2009;2:437-44.  
14. Akansha Tripati,Ranjana Gupta,Subhini A. Saraf. PLGA Nanoparticles of Anti Tubercular 
Drug:Drug Loading And Release Studies Of a Water Insoluble Drug.Faculty of Pharmacy, 
BBDNITM,Sector-1,Dr. Akhilesh Das Nagar,Fazabad Road,Lucknow,227105(UP), India July – 
September 2010.. 
15. Raviglione MC, Dixie ES Jr, Kochi A. Global Epidemiology of Tuberculosis. JAMA 1995;273:220-6. 
16. De Jong BC, Antonio M, Gagneux S. Mycobacterium africanum-review of an important cause of 
human tuberculosis in West Africa. PLoS Negl Trop Dis 2010;4:744 
17. Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for worldwide tuberculosis control under 
the WHO DOTS strategy. Directly observed short-course therapy. Lancet 1998;352:1886-91.(I -1) 
18. Chakraborty AK. Epidemiology of tuberculosis: Current status in India. Indian J Med Res 
2004;120:248-76. 
19. Walls T, Shingadia D. Global epidemiology of paediatric tuberculosis. J Infect 2004;48:13-22. 
20. Dye C. Global epidemiology of tuberculosis. Lancet 2006;367:938–40. 
21. Burzynski J, Schluger NW. The epidemiology of tuberculosis in the United States. Semin Respir 
Crit Care Med 2008;29:492-8. 
175 
 
22. Pepper DJ, Meintjes GA, McIlleron H, Wilkinson RJ. Combined therapy for tuberculosis and HIV-
1: the challenge for drug discovery. Drug Discov Today 2007;12:980-9. 
23. Mitchison DA. Mechanism of drug action in short-course chemotherapy. Bull Int Union Tuberc 
1985;65:30-7. 
24. Iseman MD, Madsen LA. Drug-resistant tuberculosis. Clin chest Med 1989;10:341-53. 
25. Heifects LB, Lindholm-Levy P. Comparison of bacterial activities of streptomycin, amikacin, 
kanamycin, and capreomycin against Mycobacteerium avium and M tuberculosis. Antimicrob 
Agents Chemother 1989;33:1298-1301. 
26. Garg RK. Classic diseases revisited: Tuberculosis of the central nervous system. Postgrad Med J 
1999;75:133-140 
27. Ragno R, Marshall GR, Di Santo R, Costi R, Massa S, Rompei R, et al. Antimycobacterial pyrroles: 
synthesis, anti-Mycobacterium tuberculosis activity and QSAR studies. Bioorg Med Chem 
2000;8:1423–32. 
28. Hu Y, Coates AR, Mitchison DA. Sterilising activities of fluoroquinolones against rifampintolerant 
populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47:653–7.  
29. Cole ST, Alzari PM. TB-a new target, a new drug. Science 2005;307:214–5. 
30. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, et al. OPC-67683, 
a nitro-dihydro-imidaooxazole derivativewith promising action against tuberculosis in vitro and 
in mice. PLoS Med 2006;3:2131–44.  
31. Ginsberg AM, Spigelman M. Challenges in tuberculosis drug research and development. Nat 
Med 2007;13:290–94. 
32. Nuermberger E, Tyagi S, Williams KN, Rosenthal I, Bishai WR, Grosset JH. Rifapentine, 
moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am J 
Respir Crit Care Med 2005;172:1452–6.  
176 
 
33. Chen P, Gearhart J, Protopopova M, Einck L, Nacy CA. Synergistic interactions of SQ109, a new 
ethylene diamine, with front-line antitubercular drugs in vitro. J Antimicrob Chemother 
2006;58:332–7. 
34. Panchagnula R, Rungta S, Sancheti P, Agrawal S, Kaul C. In vitro evaluation of food effect on the 
bioavailability of rifampicin from antituberculosis fixed dose combination formulations. 
Farmaco. 2003;58:1099-1103. 
35. Koup JR, Williams-Warren J, Viswanathan CT, Weber A, Smith AL. Pharmacokinetics of Rifampin 
in Children II. Oral bioavailability. Ther Drug Monit 1986;8:17-22. 
36. Saranjit Singh, Mariappan TT, Sankar R, Sarda N, Baljinder Singh. A critical review of the 
probable reasons for the poor/variable bioavailability of rifampicin from anti- tubercular fixed-
dose combination (FDC) products, and the likely solutions to the problem. Int J Pharm 
2001;228:5-17. 
37. C.J.Shishoo,S.A.Shah, I.S. Rathod, S.S. Savale, M.J. Vora .Impaired bioavailability of  rifampicin in 
presence of isoniazid from fixed dose combination formulation, int  J Pharm. 2001; 228:53–67. 
38. Singh S, Mariappan TT, Sankar R, Sarda N, Singh B. A critical review of the probable reasons for 
the poor/variable bioavailability of rifampicin from anti-tubercular fixed dose combination (FDC) 
products, and the likely solutions to the problem. Int J Pharm 2001;228:5-17. 
39. Shishoo CJ, Shah SA, Rathod IS, Savale SS, Kotecha JS, Shah PB. Stability of rifampicin in 
dissolution medium in presence of isoniazid. Int J Pharm 1999;190:109-23. 
40. Jindal KC, Chaudhary RS, Singla AK. Gangwal, SS Khanna S. Dissolution test method for 
rifampicin–isoniazid fixed dose formulations. J Pharm Biomed Anal 1994;12:493-97. 
41. Sankar R, Sharda N, Singh S. Behavior of decomposition of rifampicin in the presence of isoniazid 
in the pH range of 1-3. Drug Dev Ind Pharm. 2003;29:733-8.  
177 
 
42.  Mariappan TT, Singh S. Regional gastrointestinal permeability of rifampicin and isoniazid (alone 
and their combination) in the rat. Int J Tuberc Lung Dis 2003;7:797-803. 
43. .Gambhire Vaishali , Bhalekar Mangesh , Gambhire Makarand . Development of rifampicin 
nanoparticles by 32 factorial design. International Journal of Pharmaceutical Sciences and 
nanotechnology 2010 ; 3(3) : 1085-1091 
44. . Magdalena Stevanovi,Dragan Uskokovi.Poly(lactide-co-glycolide)-based Micro and 
Nanoparticles for the Controlled DrugDelivery of Vitamins. 
45. . L. Zhang , D. Pornpattananangkul, C.-M.J. Hu and C.-M. Huang. Development of Nanoparticles 
for Antimicrobial Drug Delivery .Current Medicinal Chemistry, 2010; 17: 585-594. 
46. Prabakaran D, Singh P, Jaganathan KS, Vyas SP: Osmotically regulatedasymmetric 
capsular systems for simultaneous sustaineddelivery of anti-tubercular drugs. J Contr Rel 
2004, 95(2):239-248. 
47. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B: Poly (DL-lactide-co-
glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental 
tuberculosis. J Antimicrob Chemother 2003, 52:981-986. 
48. Kailasam S, Daneluzzi D, Gangadharam PRJ: Maintenance of therapeutically active levels 
of isoniazid for prolonged periods in rabbits after a single implant of biodegradable 
polymer. Tuber Lung Dis 1994, 75(5):361-365. 
49. Dutt M, Khuller GK: Sustained release of isoniazid from a single injectable dose of poly 
(DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. 
IntJ Antimicrob Agents 2001, 17:115-122. 
50. Ain Q, Sharma S, Garg SK, Khuller GK: Role of poly [DL-lactideco-glycolide] in 
development of a sustained oral delivery systemfor antitubercular drug(s). Int J Pharm 
2002, 239(1–2):37-46.  
178 
 
51. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B: Poly (DL-lactide-co-glycolide) 
nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J 
Antimicrob Chemother 2003, 52:981-986. 
52. Zhou H, Zhang Y, Biggs DL, Manning MC, Randolph TW, ChristiansU, Hybertson BM, 
Ng K: Microparticle-based lung delivery of INH decreases INH metabolism and targets 
alveolar macrophages. J Contr Rel 2005, 107(2):288-299. 
53. Barrow EL, Winchester GA, Staas JK, Quenelle DC, Barrow WW. Use of microsphere technology 
for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. 
Antimicrob Agents Chemother 1998; 42:2682-2689. 
54. Sharma R, Saxena D, Dwivedi AK, Misra A. Inhalable microparticles containing drug combinations 
to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res 2001; 
18:1405-1410. 
55.  Suarez S, O'Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, Hickey 
AJ: Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J 
Antimicrob Chemother2001, 48:431-434. 
56. O'Hara P, Hickey AJ: Respirable PLGA microspheres containing rifampicin for the 
treatment of tuberculosis: manufacture and characterization. Pharm Res 2000, 17:955-
961. 
57.   Zahoor A, Pandey R, Sharma S, Khuller GK: Pharmacokinetic and pharmacodynamic 
behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses. Int 
J Antimicrob Agents 2006, 27(5):409-416. 
58. Pandey R, Khuller GK: Solid lipid particle-based inhalable sustained drug delivery 
system against experimental tuberculosis. Tuberculosis 2005, 85(4):227-234. 
179 
 
59. Vyas SP, Kannan ME, Sanyog Jain, Mishra V, Singh P: Design of liposomal aerosols for 
improved delivery of rifampicin to alveolar macrophages. Int J Pharm 2004, 269(1):37-
49. 
60. Walter Wehrli. Rifampin: Mechanisms of Action and Resistance. Rev Infect Dis 1983;5:407-11. 
61. Goodman and Gilman: The pharmacological basis of therapeutics. 10th ed. edited by Joel G. 
Hardman and Lee E. Limbird, published by McGraw-Hill Medical Publishing Division; .p1706. 
62. Van Scoy RE, Wilkowske CJ. Antituberculosis agents. Mayo Clin Proc 1987;62:1129-36. 
63. Chow AW, Jewesson PJ. Pharmacokinetics and Safety of Antimicrobial Agents during Pregnancy. 
Rev Infect Dis 1985;7:287-313. 
64. Erlich Henry, Doolittle WF, Volker Neuhoff. Molecular Biology of Rifomycin. New York, NY: MSS 
Information Corporation, 1973. pp. 44-45, 66-75, 124-130. 
65. Meyer H, Mally J. Über Hydrazinderivate der Pyridincarbonsäuren. Monatsheftefür Chemie und 
verwandte Teile anderer Wissenschaften 1912; 23: 393-414. 
66. Indian Pharmacopeia 2010 volume II page 1515-1517. 
67. Winder FG, Collins PB. Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium 
tuberculosis. J Gen Microbiol 1970; 63: 41-8. 
68. Baciewicz AM & Self TH: Isoniazid interactions. South Med J 1985; 78:714-718. 
69. Siskind MS, Thienemann D, Kirlin L. Isoniazid-induced neurotoxicity in chronic dialysis patients: 
report of three cases and a review of the literature. Nephron 1993; 64: 303-6. 
70. Jimenez-Lucho VE, Del Busto R, Odel J. Isoniazid and ethambutol as a cause of optic neuropathy. 
Eur J Respir Dis 1987; 71: 42-5. 
71. Parasuram S, Ravendran R, kesavan R. Blood sample collection in small laboratory animals. J 
Pharmacol Pharmacother 2010;1:87-93. 
180 
 
72. Karan RS, Bhargava VK, Garg SK. Effect of trikatu, an Ayurvedic prescription, on the 
pharmacokinetic profile of rifampicin in rabbits. J Ethnopharmacol 1999;64:259-64. 
73. Bhavika Mohan, Nishi Sharda, Saranjit Singh, Evaluation of the recently reported USP gradient 
HPLC method for analysis of anti-tuberculosis drugs for its ability to resolve degradation 
products of rifampicin, J.pharm and biomedical analysis 2003; 31:607-612. 
74. Shargel L, Wu-Pong S, Yu ABC. Applied Biopharmaceutics and Pharmacokinetics. 5th ed. p. 46. 
75.  Doshi BS Bhate AD,Chauhan BL,Parkar TA, Kulkarni RD.Pharmakinetics interaction of oral RIF 
and INH in normal subjects.indian Drugs 1986;133:1076-80. 
76. Gallo GG, Radaelli P.Rifampicin. Academic Press, New York, Analytical profile of Drug substances 
1976;5:467-515. 
77. Maggi N ,pasqualucci CR,Ballotta r,Sensi p.Rifampicin:Anew orally active 
rifampicin.Chemotherapia 1966;11:285-92. 
78. Muller RH ,Souto EB, Goppert TM, Gohla S Production of biofunctionalized solid lipid 
nanoparticles (SLN) for site-specific drug delivery.Nanotechnologies for the life sciences Vol 
2;Biological and pharmaceutical nanoparticles. Weinheim; Kumar CSSR, WILEY-VCH Verlag 
Gmbh & Co.KGaA;2006.  
 
 
 
 
 
 
 
